



RESIDENT VOICE
**Resident Innovations
 in Medicine**
 SEE PAGE 18



FACEPS IN THE CROWD
**Mohamed Hagahmed, MD,
 FACEP, FAAEM, EMT-P**
 SEE PAGE 4



SKEPTICS' GUIDE
**Go Big or
 Go Small?**
 SEE PAGE 15

WILEY

American College of
 Emergency Physicians®
 ADVANCING EMERGENCY CARE

ACEP Now

The Official Voice of Emergency Medicine

MARCH 2022


Volume 41 Number 3

FACEBOOK/ACEPFAN

TWITTER/ACEPNOW

ACEPNOW.COM

PLUS



WORLD TRAVELERS
Going Global
 SEE PAGE 12



HISTORY
We Dissent
 SEE PAGE 10



FIND IT ONLINE
 For more clinical stories and
 practice trends, plus commen-
 tary and opinion pieces, go to:
www.acepnow.com

Tres Bernhard (left), deputy chief of staff for Troy Carter, former Louisiana state senator and now U.S. Representative in Congress, and Dr. Kuo (right).

“If Not Me, Then Who?”

by JAMIE KUO, MD

Last year’s scope of practice battle in Louisiana helped ignite my new passion for state-level advocacy work, and it can for you, too.

In spring 2021, HB 495, a bill submitted by Rep. Barry Ivey, was progressing quickly through the Louisiana legislative process. It was a bill that would grant full practice authority to advanced practice registered nurses, who would no longer need to collaborate with a supervising

CONTINUED on page 8

JAMIEDO KUO

The Cures Act

Adjusting to new rules in emergency departments

by LINDA KOSSOFF

Five years after the U.S. Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology (ONC) developed the 21st Century Cures Act allowing patients expanded access to their electronic health records, the sweeping law is, for all practical purposes, in full effect. And although the increased transparency that the law represents is empowering to patients, it does require adjustments for physicians.

“There’s always been this veil of mystery around physicians’ notes,” said Áine Yore, MD, an emergency physician affiliated with Providence Regional Medical Center in Everett, Washington. “Before [the Cures Act], if the patient wanted to see their whole chart, they would have to request it from a medical records department, pay a fee and maybe wait weeks for it to be released.” Today, pa-

CONTINUED on page 6

PERIODICAL

WILEY PERIODICALS LLC
 Journal Customer Services
 111 River Street
 Hoboken, NJ 07030-5790
 If you have changed your address or wish to contact us, please visit our website
www.wileycustomerhelp.com

ACEP Now
 The Official Voice of Emergency Medicine

TOX Q&A
**Purity &
 Poison**
 PAGE 17

JASON HACK (OLEANDER PHOTOGRAPHY)

ACEP Now

The Official Voice of Emergency Medicine

EDITORIAL STAFF

MEDICAL EDITOR Cedric Dark, MD, MPH, FACEP cdark@acep.org	RESIDENT FELLOW Cara Borelli, DO borelli@uthscsa.edu
EDITOR Danielle Galian dgalian@wiley.com	ASSOCIATE EDITOR Catherine A. Marco, MD, FACEP cmarco@acep.org
ART DIRECTOR Chris Whissen chris@quillandcode.com	

ACEP STAFF

EXECUTIVE DIRECTOR/CHIEF EXECUTIVE OFFICER Susan Sedory, MA, CAE ssedory@acep.org	SENIOR VICE PRESIDENT, COMMUNICATION Jana Nelson jnelson@acep.org
CHIEF OPERATING OFFICER Robert Heard, MBA, CAE rheard@acep.org	MANAGING DIRECTOR, CONTENT AND COMMUNICATION INTEGRATION Nancy Calaway, CAE ncalaway@acep.org
SENIOR CONTENT MANAGER Jordan Grantham jgrantham@acep.org	

PUBLISHING STAFF

PUBLISHING DIRECTOR Lisa Dionne Lento ldionnelen@wiley.com	ASSOCIATE DIRECTOR, ADVERTISING SALES Steve Jezzard sjezzard@wiley.com
--	--

ADVERTISING STAFF

DISPLAY & CLASSIFIED ADVERTISING
Kelly Miller
kmiller@mrsvica.com
(856) 768-9360

EDITORIAL ADVISORY BOARD

James J. Augustine, MD, FACEP	Ricardo Martinez, MD, FACEP
Richard M. Cantor, MD, FACEP	Sandra M. Schneider, MD, FACEP
L. Anthony Cirillo, MD, FACEP	Jeremiah Schuur, MD, MHS, FACEP
Jonathan M. Glauser, MD, MBA, FACEP	Robert C. Solomon, MD, FACEP
Michael A. Granovsky, MD, FACEP	Annalise Sorrentino, MD, FACEP
Sarah Hoper, MD, JD, FACEP	Peter Viccellio, MD, FACEP
Mitchell Kentor, MD	Rade B. Vukmir, MD, JD, FACEP
Phillip Luke LeBas, MD, FACEP	


INFORMATION FOR SUBSCRIBERS

Subscriptions are free for members of ACEP and SEMPA. Free access is also available online at www.acepnow.com. Paid subscriptions are available to all others for \$334/year individual. To initiate a paid subscription, email cs-journals@wiley.com or call (800) 835-6770. ACEP Now (ISSN: 2333-259X print; 2333-2603 digital) is published monthly on behalf of the American College of Emergency Physicians by Wiley Periodicals LLC, 111 River Street, Hoboken, NJ 07030-5774. Periodical postage paid at Hoboken, NJ, and additional offices. Postmaster: Send address changes to ACEP Now, American College of Emergency Physicians, P.O. Box 619911, Dallas, Texas 75261-9911. Readers can email address changes and correspondence to acepnow@acep.org. Printed in the United States by Sheridan of Ohio (SOH), Brimfield, OH. Copyright ©2022 American College of Emergency Physicians. All rights reserved. No part of this publication may be reproduced, stored, or transmitted in any form or by any means and without the prior permission in writing from the copyright holder. ACEP Now, an official publication of the American College of Emergency Physicians, provides indispensable content that can be used in daily practice. Written primarily by the physician for the physician, ACEP Now is the most effective means to communicate our messages, including practice-changing tips, regulatory updates, and the most up-to-date information on healthcare reform. Each issue also provides material exclusive to the members of the American College of Emergency Physicians. The ideas and opinions expressed in ACEP Now do not necessarily reflect those of the American College of Emergency Physicians or the Publisher. The American College of Emergency Physicians and Wiley will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein. The views and opinions expressed do not necessarily reflect those of the Publisher, the American College of Emergency Physicians, or the Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the American College of Emergency Physicians, or the Editors of the products advertised.



Effectively Run an Emergency Department

WITH THIS COMPREHENSIVE, PRACTICAL TEXT



COMPLETE, EXPERT COVERAGE OF EVERY IMPORTANT MANAGEMENT TOPIC, INCLUDING:

- Leadership Principles
- Operations
- Informatics
- Quality and Service
- Finance
- Reimbursement
- Contracts
- Legal and Regulatory Issues
- Malpractice
- Human Resources

NEW! SECOND EDITION

Order Today!

Print Edition ACEP Member Price \$229

ACEP Resident Member Price \$169 | Nonmember Price \$329

You can also order the eBook

eBook Edition ACEP Member Price \$189

ACEP Resident Member Price \$149 | Nonmember Price \$279

Get the guidance and expertise required to deliver consistent, rapid, high-quality care with *Emergency Department Management*

bookstore.acep.org
OR CALL 844.381.0911



ACN_0322_MC1542_0222

Grand Hyatt Washington | May 1-3, 2022 | acep.org/lac

Leadership & Advocacy Conference

Make Your Voice Heard on Capitol Hill
with ACEP's Leadership and Advocacy Conference (LAC)

LAC returns to Washington, DC this May. Don't miss your chance to **reconnect** with your peers, **advocate** for your specialty, and **engage** with members of Congress.



ADVOCATE
for Emergency Medicine

ENGAGE
with Members of Congress

CONNECT
with EM Leaders

Approved for AMA PRA Category 1 Credit™



REGISTER TODAY!

ACN_0322_MC1541_0222

ACEP Now Welcomes New Associate Editor

Catherine Marco, MD, FACEP, is the newest member of the *ACEP Now* editorial team. In her role as Associate Editor, Dr. Marco will work in conjunction with Medical Editor in Chief Cedric Dark, MD, MPH, FACEP, to primarily oversee the evidence-based medicine content within the magazine. Dr. Marco is Professor of Emergency Medicine at Wright State University and Research Director at the Wright State University Department of Emergency Medicine.

Learn More About Consolidation and its Effects

A two-part series on ACEP's regulatory blog tackles both sides of the consolidation coin. The first blog, focused on recent federal efforts to address hospital and physician consolidation, discusses trends seen in the current health care system and summarizes the steps Congress and the Biden Administration have taken to address it. The second blog, focused on insurer consolidation and the bad insurer behavior that comes with it, dives deep into the Medicare and Medicaid data and how it affects emergency medicine (EM). Read the full series and subscribe to ACEP's weekly regulatory blog at acep.org/regsandeggs.

Dr. Lorna Breen Bill Passes

On Feb. 17, the Senate passed the ACEP-supported Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667) by voice vote, clearing the way for President Biden to sign it into law. H.R. 1667 takes significant steps to prevent physician suicide, reduce burnout, and address major concerns about the mental health of emergency physicians and care teams. ACEP was instrumental in the work to develop and pass this bill, and ACEP members rallied around this bill from its inception. "ACEP is grateful that Congress recognizes the weight of the challenges shouldered by medical professionals on the front lines throughout the pandemic," said Gillian Schmitz, MD, FACEP, president of ACEP. "This important legislation honors Dr. Breen's legacy and charts a path forward that helps limit the barriers currently preventing many emergency physicians from seeking the mental health care they need."

ACEP Sets Upcoming Advocacy Priorities

Every year, ACEP's Federal Government Affairs Committee and the ACEP advocacy team work together to establish broad goals for the upcoming legislative session.

- 1. Mental Health:** ACEP priorities include strengthening the mental/behavioral health care workforce, increasing integration, coordination, and access to mental health care, ensuring parity, furthering the use of telehealth, and improving access especially for children and young adults. ACEP also continues urging Congress to include physician mental health and burnout as necessary considerations in any comprehensive mental health policy initiatives.
- 2. Medicare Reimbursement:** At the end of 2021, Congress acted to avert *most* Medicare reimbursement cuts that were slated to affect many physicians, including EM.

ACEP aims to work with them this year to develop a longer term solution that provides stability and appropriate payment for physician services without setting specialties against one another due to budget neutrality requirements.

- 3. EM Workforce:** ACEP is developing legislation to help address the unique concerns of the EM workforce and to create incentives to help fill in gaps in emergency care in rural and underserved communities in the United States. This legislation coincides with ACEP's ongoing advocacy on Capitol Hill as legislators examine growing

health care workforce shortages and other challenges facing the health care system.

- 4. EM Due Process:** ACEP is concerned by reports of health care workers being threatened or silenced for speaking out about public health and safety concerns, especially during the pandemic. ACEP is working closely with legislators to reintroduce the "Emergency Room Hero and Patient Safety Act" that would ensure every EM physician has medical staff due process protections.

- 5. Expanding Access to Services for OUD Patients:** ACEP disagrees with the re-

quirement that physicians must apply for a special waiver in order to prescribe buprenorphine. ACEP supports the bipartisan, bicameral "Mainstreaming Addiction Treatment Act" and is urging Congress to reauthorize the successful "Alternatives to Opioids (ALTO) in the Emergency Department Act."

All ACEP members are invited to join the cause by participating in the upcoming Leadership & Advocacy Conference, May 1-3 (acep.org/LAC). 📍



Minutes Matter

In 28 minutes, you can:

- ✓ Accelerate proper treatment
- ✓ Improve the patient experience
- ✓ Minimize loss-to-care and callbacks
- ✓ Increase patient throughput



LEARN MORE

1-833-GoVisby (1-833-468-4729)
sales@visbymedical.com
www.visbymedical.com

visby medical

Visby Medical Sexual Health Click Test

— For self-collected vaginal swabs —

This device has received 510(k) clearance by the FDA and granted a CLIA waiver.

PL-000138 Rev A

RESIDENCY SPOTLIGHT STATEN ISLAND UNIVERSITY HOSPITAL EMERGENCY MEDICINE

Instagram: @siuhemresidency

Twitter: @statenislendem

Location: Staten Island, NY

Year founded: 2010

Number of residents: 30, 10 per class

Program length: 3 years



SIUH EMERGENCY MEDICINE

Residents taking part in "dress like the Program Director Dr. Caputo" at SIUH.

Why did you choose this program?

We get exposure and a diverse experience at two of only three hospitals on Staten Island: an academic level 1 trauma center (SIUH North) and community-based site (Prince's Bay Campus). Our residency is located one bridge away from Brooklyn/Manhattan and New Jersey, so we get the best of both worlds! The faculty provide unmatched medical education through our first-rate weekly resident conferences, simulation sessions, and ultrasound teaching. Their dedication and our hard work have paid off as we are the current NYC SimWars and NYC Battle of the Borough Lecture competition champions.

How do residents relax during their downtime?

Competing in weekly interdepartmental resident basketball league games (EM usually wins!), weekend strolls on the Midland Beach boardwalk, hiking at nearby mountains, brunch/karaoke in the city, hot pot/korean bbq after conference. We also bond over wellness events including Friendsgiving, Six Flags, TopGolf, escape rooms, free concert tickets and VIP suite at the Prudential Center, BBQ at our APD's house, and hiking upstate!

—Chief Residents (PGY3): Tazeen Abbas, MD; Wayne Fu, MD, MBA; Danielle Langan, DO

FACEPs IN THE CROWD

Get to know the Fellows of the American College of Emergency Physicians

MOHAMED HAGAHMED, MD, FACEP, FAAEM, EMT-P

Clinical Assistant Professor, Department of Emergency Medicine; UPP Director of Diversity, Recruitment and Relations University of Pittsburgh Medical Center; Associate Medical Director for the Center of Emergency Medicine

New ACEP Fellow Dr. Mohamed Hagahmed's background informs his unique perspective. He fled Sudan in his early teens and lived in Germany before coming to America, so he knows what it's like to feel out of place. He works to increase inclusion inside and outside the ED because he believes feeling seen, heard and supported can make all the difference.



MOHAMED HAGAHMED

'Should I talk about it?' I need to hear a word of support.

One morning, my colleague texted me to ask how I'm doing and what the situation is like in Sudan. That simple text message kind of turned a switch in my mind. I felt like, 'Wow—somebody else cares?' And to me, that feeling and message gave me hope. A simple text message has the power of completely transforming how you feel. He asked me what he could do to help me or support me. I said, 'Brother, you have no idea.

You helped me so much with just a simple text. You helped me so much because now I don't feel alone anymore.'

And that's what inclusion means to me. Inclusion means that I know how to pronounce your name, the way you want it to be pronounced. That you are part of us. Your needs are also our needs. Your emotional support is our emotional support. +

Q: What does inclusion mean to you?

Dr. Hagahmed: One thing we can do is simply acknowledge what's happening in that person's life. I'm originally from Sudan, and right now the country is going through a lot of turmoil. There is an uprising, dictatorship, reckless killing and rape. It's been going on for months and months. I feel stressed and uneasy about what's going to happen to [my family members in Sudan]. I go to work, and I feel lonely. I think to myself,

5 Fun Things with Dr. Hagahmed

- 1. Listening to:** Miles Davis if I'm relaxing. Hip hop, like DMX, when I'm working out.
- 2. Reading:** *Atlas of the Heart* by Brené Brown. She's my new favorite author.
- 3. Watching:** Scrubs—I've been watching and re-watching the show since medical school. It's so funny. It lifts my spirits.
- 4. Caffeinating with:** Big Dog Coffee—It's a local place here in Pittsburgh. I grind my own coffee at home—it's a ritual that brings me joy ... and smells amazing.
- 5. Dreaming of:** Traveling to Europe—specifically Germany, where I lived after fleeing Sudan as a young teenager. And I'd like to tell some of the people who doubted I would ever make it in medicine: I'm here now. I made it.

KNOW AN EMERGENCY PHYSICIAN WHO SHOULD BE FEATURED IN "FACEPs in the Crowd"? SEND YOUR SUGGESTIONS TO ACEPNOW@ACEP.ORG. LEARN HOW TO BECOME A FACEP AT WWW.ACEP.ORG/FACEPSINTHECROWD.

2022 Course Topics

- IV Ketamine for Depression and Suicidality in the ED?
- Is Thrombolysis Needed Prior to Clot Extraction in Stroke?
- COVID Therapies: What Works, What Doesn't - Part 1
- COVID Therapies: What Works, What Doesn't - Part 2
- Posterior Circulation Stroke – A Tough Diagnosis
- LP for Subarachnoid Hemorrhage: Who Gets It?
- 2021 AHA Chest Pain Guidelines: Game Changer - Part 1
- 2021 AHA Chest Pain Guidelines: Game Changer - Part 2
- Bronchiolitis: Less is More
- Post Cardiac Arrest Pearls
- Pearls from *Risk Management Monthly* - Part 1
- Pearls from *Risk Management Monthly* - Part 2
- Syncope – Who Is at Serious Risk?
- Tranexamic Acid – Lessons Learned
- Importance of Shared Decision Making
- The 2021 AAP Guidelines for Febrile Infants - Part 1
- The 2021 AAP Guidelines for Febrile Infants - Part 2
- PE – Overtesting / Disposition
- Critical Care Grab Bag
- Trauma Pearls from the Recent Medical Literature
- Emergency Medicine New Products - Part 1
- Emergency Medicine New Products - Part 2
- Sexually Transmitted Infections – 2021 Guidelines
- New Advances in Prehospital Care
- Visual Diagnosis Challenges - Part 1
- Visual Diagnosis Challenges - Part 2
- What's New in ED Airway Management?
- Reader Beware – Predatory Publishing / Preprints
- Important Recent EM Literature - Part 1*
- Important Recent EM Literature - Part 2*
- ED Staffing and Operations Forum*
- Diagnostic and Therapeutic Controversies*

Topics listed with an asterisk () are 90-minute faculty panel discussions; all other topics are 30 minutes.

*Experience the Course
Enjoyed by Over 60,000
of Your Colleagues!*



37th Annual Series

EMERGENCY MEDICINE & ACUTE CARE / 2022

A CRITICAL APPRAISAL

In Collaboration With **EM:RAP**
Emergency Medicine: Reviews and Perspectives

**TIME FOR A
BREAK!**

- ✓ 28 State-of-the-Art Topics
- ✓ Focused on Clinical Questions
- ✓ Four 90-Minute Faculty Panels
- ✓ Literature-Derived Evidence
- ✓ Seasoned Clinical Faculty
- ✓ 8 Top Dates & Destinations



Las Vegas, NV
April 9-12, 2022




New Orleans, LA
April 27-30, 2022 (Jazz Fest)



Hilton Head, SC
May 4-7, 2022



San Diego, CA
June 7-10, 2022



San Francisco, CA
June 16-19, 2022



New York, NY
June 22-25, 2022



Vancouver, BC, Canada
July 19-22, 2022



Key West, FL
November 28 - Dec. 2, 2022

Register Today at www.EMACourse.com

or Call 1-800-458-4779 (9:00am-4:30pm ET, M-F)

Jointly Sponsored by

**THE CENTER FOR
MEDICAL EDUCATION**

EM:RAP
Emergency Medicine: Reviews and Perspectives

CEME
Center for Emergency Medical Education

tients log in to their record to easily view appointment information, medication lists, lab results and, now, physicians' clinical notes.

Given this latest development, emergency physicians weigh in on the law's unique impact in the emergency department.

Sparking a Conversation

Any patient who can connect to an online patient portal can gain access to their information, and this becomes a jumping-off point for doctor-patient discussion about their health status. "Patients accessing their information in real-time fuels more questions about their results, leading to meaningful conversations with physicians," explained



Dr. Indira Gowda


Indira Gowda, MD, an emergency physician at University of California Los Angeles Medical Center. "As a result, patients end up better informed." The easy availability of information also enables patients to share it with family members or friends who may help them better interpret their results. "Research has shown this is especially true for non-English-speaking patients," added Dr. Gowda.

To translate those real-time results into informative discussions, Dr. Yore is always prepared to give impromptu anatomy lessons in the patient room. "I'll walk in and say, 'You've got a kidney stone,' and they'll say, 'Yeah, doctor, we know—we saw that an hour ago.' And I'll say, 'Okay, well, very good, let's talk a little more about this,'" she explained. "And that gives me an opportunity to provide more education."

Another potential benefit can be seen in cases of incidental findings. "You do a chest X-ray to look for pneumonia, and it shows a spot on one of the lungs. Although this is a double-edged sword because now the patient sees this and the radiologist is saying, 'Well, you have to rule out cancer,' it also keeps us honest," Dr. Yore said. "Maybe in the past some of us haven't been too diligent about disclosing incidental findings and saying to patients, 'This is probably nothing, but you do need to follow it up and get that CT in six months,' or whatever the recommendation is. So the patient is now independently aware, and I think this increases our compliance to that communication with patients."


The degree to which some of the benefits of the Cures Act apply to the emergency department setting is not clear. "[The Cures Act] is supposed to help improve the patient-doctor relationship and improve trust and communication amongst patients and providers, but this has only really been studied in non-emergency, acute care settings, such as the outpatient clinic," said Dr. Gowda. One difference lies in the very nature of the emergency physician-patient relationship, which by nature is brief and limited, and any opportunity to educate patients plummets when that emergency department (ED) visit ends. Even patients who are inclined to reach out post-visit are likely to have a difficult time. "We come and we go. We work weird hours," Dr. Yore said. "An oncologist's relationship with their patient may be measured over months and years, whereas I have 180 minutes with each patient, by and large."

Has a patient in your ED discovered a lab result, via their EHR portal, before you knew it?




Percentage of patients who indicated they saw their lab results before their physician.

Are you concerned about liability when you share notes with patients?



Percentage of physicians who have liability concerns.

Are you / do you anticipate spending more time on documentation as a result of the mandate?



Percentage of physicians who may or may not spend more time on documentation.

Potential Pitfalls

In a recent survey of ACEP members on the 21st Century Cures Act, two-thirds of 134 respondents reported cases where patients knew their test outcome before their clinician could discuss it with them. This increased the likelihood of patients discovering a bad result on their own. Dr. Gowda cites an instance in

which a woman discovered that she had had a miscarriage by reading the final impression of her radiology report. "I feel like providing patients this information without a human interaction can create more harm than good," she said.

A more common scenario is the patient who experiences undue anxiety over an abnormal

but clinically irrelevant test result. "When an ED patient is scared and these results are trickling in electronically, a trivial abnormality or errant phrase may get magnified or misinterpreted," explained Nicholas Genes, MD, PhD, FACEP, an emergency physician at New York University (NYU) Langone Health, clinical associate professor in the department of emer-

GRAPHICS: ACEP

gency medicine at NYU Grossman School of Medicine and chair of ACEP's Health IT Committee. "I remember a patient with a history of anxiety who brought up so many details from prior notes that what should have been a quick visit ended up feeling like a cross-examination where I had to discuss my own and other doctors' medical decision making. Being transparent is usually a great thing, but sometimes in a busy ER we don't need to revisit clinical notes written months ago."

Although Dr. Genes believes that note sharing is generally a good thing, he would like to see ED patients' notes digitally released toward the conclusion of their visit, after the physician has had an opportunity to review results and explain them. In efforts to enact a change, he has worked with Jeff Davis, ACEP's director of regulatory and external affairs, on outreach to the ONC. They formally requested that regulations be altered to allow for emergency departments to delay sharing lab results and clinical notes with patients for a 24-hour period or at the least until the patient is discharged from the emergency department. The recommendation was not accepted, however, and ACEP's effort to advocate for regulations that support the unique needs of the emergency department continues.

Although there are provisions written into the Cures Act that allow doctors to censor information and prevent a patient from seeing it, many physicians are either not aware of this option or do not know how to use it. "There are often no clear guidelines on when censoring is appropriate," Dr. Gowda said. "For example, there are exceptions to patients having immediate access to their chart if it would result in harm to the patient, but *harm* is not clearly defined and doesn't always refer to emotional harm—as in learning that you had a miscarriage via a radiology report or ED note.

"I think increased awareness of what patients may access and knowing the appropriate steps physicians can take to censor information when needed will help improve communication," Dr. Gowda continued. "I think this responsibility often falls on the hospital administration to clearly distribute these guidelines."

Charting in a New Climate

Now that patients can view physicians' clinical notes, should doctors adjust their charting habits? Most say little change should be necessary, as clinical notes are still meant for multiple audiences, including other clinicians as well as billing, compliance and medicolegal departments. "I still chart from a medicolegal perspective and to help other providers understand my decision-making process," said Dr. Gowda.

In charting, accuracy has always been paramount. With the new law in place, patients are more inclined to scour their charts in search of errors to report. "There is literature out there, a primary care physicians study, regarding patients who do this," said Dr. Yore.¹ "We need to be aware of that those patients are going to contact us to say, 'This is wrong, please fix it.' And if it is wrong, we need to be open to amending our charts."

Some physicians have expressed concern that patient accessibility to their notes may open them up to harsh and unjustified criti-

cism as every recorded remark and observation is scrutinized. Dr. Yore's advice: "If you're not comfortable with your chart being blown up into a 4 × 6 poster in front of a jury, you shouldn't be putting it in the medical record." She cautions colleagues to be mindful of the language used in charts and how people are going to perceive it. "This is particularly relevant in the emergency department, where we see a lot of people with substance abuse issues and mental health issues, marginalized people, homeless people, people of different racial, gender/sexual identities, etc.," she said. "It's easy to inadvertently—or even as a result of not caring—use language that isn't appropriate. For instance, you can describe someone as being 'drunk,' but that's not exactly neutral language. A suitable

description of this patient might read, 'They had a wide, shuffling gait, and speech was slurred.' This way, you haven't exposed yourself as coming into that interaction with a set of implicit biases."

Some inappropriate word choices for charting are not quite so obvious. Dr. Yore cites the phrase "frequent flier," a common term her department uses to refer to patients who visit the emergency department regularly, often with the same complaint. "That phrase should never find its way into a chart, but it does," she said, suggesting that writing "this patient is well-known to this emergency department" would be a better choice. Along these same lines, Dr. Gowda now refrains from using certain descriptors: "For example, instead of stating that a patient is obese/overweight, I state

the patient's BMI."

Some physicians express concerns about patients' inability to understand the medical jargon used in charts, but "this is the age of Google," reminded Dr. Yore. "People who are invested in their care and motivated to understand their condition can look up the terms and learn more than they would ever want. To the degree that the jargon is useful for precise and concise communication with other members of a health care team, I am okay with it." +

Reference

1. Bell SK, Delbanco T, Elmore JG, et al. Frequency and types of patient-reported errors in electronic health record ambulatory care notes. *JAMA Netw Open*. 2020;3(6):e205867.

LINDA KOSSOFF is a freelance medical writer based in Woodland Hills, California.



Dr. Nicholas Genes

1
Infusion

30
Minutes

0
Admissions

A single 1500-mg dose of DALVANCE provides a **full course of therapy**,¹ helping your patients avoid hospitalization for daily ABSSSI treatment

Free to go **Dalvance**[®]
(dalbavancin) for injection
500 mg

INDICATION AND USAGE

DALVANCE[®] (dalbavancin) for injection is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-susceptible and methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus anginosus* group (including *S. anginosus*, *S. intermedius*, *S. constellatus*) and *Enterococcus faecalis* (vancomycin-susceptible isolates).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.

**Please see additional Important Safety Information on next page.
Please also see Brief Summary of full Prescribing Information on adjacent page
or visit https://www.rxabbvie.com/pdf/dalvance_pi.pdf.**

Dr. Kuo (front left) with ACEP members at the 2021 ACEP Leadership and Advocacy Conference in Washington, DC.



JAMIE DO KUO

physician when treating patients. As usual, I was watching from the sidelines—I'd always been passive with legislative advocacy efforts. This time, the bill passed through committee, something that had never happened before. Then the bill quickly progressed through the House floor. My stress level spiked at the realization this bill could become law, and I knew I couldn't afford to wait this out and hope for the best—I had to get involved.

By the time I joined the cause, things were looking pretty bleak. The consensus among the public was that the bill was going to pass, but Louisiana physicians from all specialties joined forces to push back against it. LA-ACEP worked together with other specialties to hire a short-term lobbyist to make a last-minute push. On the first day, the lobbyist actually was worried we hired him too late in the process, but he stayed the course and was at the capitol from dawn to dusk, spreading our message: Advanced practice nurses should not perform

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.

Infusion-related Reactions

Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, rash, and/or back pain.

Hepatic Effects

ALT elevations with DALVANCE treatment were reported in clinical trials.

***Clostridioides difficile*-associated Diarrhea**

Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

Development of Drug-resistant Bacteria

Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions in adult patients treated with DALVANCE in Phase 2/3 trials were nausea (5.5%),

headache (4.7%), and diarrhea (4.4%).

The most common adverse reaction that occurred in more than 1% of pediatric patients was pyrexia (1.2%).

Use in Specific Populations

- There are no adequate and well-controlled studies with DALVANCE use in pregnant or nursing women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DALVANCE and any adverse effects on the breast-fed child from DALVANCE or from the underlying maternal condition.
- In patients with renal impairment whose known creatinine clearance (CLcr) is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended regimen of DALVANCE is 1125 mg, administered as a single dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis. There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years of age with CLcr less than 30 mL/min/1.73m².
- Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients.

Please also see Brief Summary of full Prescribing Information on adjacent page or visit https://www.rxabbvie.com/pdf/dalvance_pi.pdf.

Reference: 1. DALVANCE® (dalbavancin) [prescribing information]. Madison, NJ: Allergan USA, Inc.; 2021.

abbvie

DALVANCE® and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company. © 2021 AbbVie. All rights reserved. US-DAV-210199 10/21

Free to go

Dalvance®

(dalbavancin) for injection

500 mg

independent unsupervised care.¹

Beginning a Grassroots Campaign

Using the power of social media, I started a physician-only Facebook group focusing specifically on this bill. While our lobbyist was at the capitol, we made a big grassroots push. We organized hundreds of physicians statewide to deluge our legislators by phone, via email, or in person. It was clear that a lot of physicians wanted to get involved and didn't know how to go about it. We kept it simple to make their voices heard; our collective voice declared to our legislators that Louisiana physicians did not support this bill.

The next month was wild! We communicated ideas and directions among physicians, our contacts, and lobbyists at the capitol. I posted daily updates with next steps (provided by our contacts) on our Facebook group

GET INVOLVED NOW!

Get plugged into ACEP's advocacy efforts by joining the 911 Grassroots Network. Open to all ACEP members, it's the only dedicated grassroots advocacy action network speaking on behalf of the specialty of emergency medicine and patients seeking emergency care.
[.org/911grassrootsnetwork](http://www.acep.org/911grassrootsnetwork)



page. Within a few days, the momentum started to change in our favor, and we knew we couldn't rest. We kept the messaging going for the next month. It was such an incredible feeling the day we found out the bill had

officially been defeated.

Going through this experience on such an intimate level, I discovered my passion for state advocacy. At the end of the 2021 session, I decided I would start advocating in my spare

time to support good health care legislation. After watching every single relevant House and Senate committee meeting, I realized our legislators are sometimes passing or not passing laws they don't fully understand. Many state representatives are former lawyers and business owners, so they can't possibly know every detail of every topic, including how their proposed policies affect patients. As a practicing emergency physician, I felt responsible to help educate them.

I enrolled in a master's program for health law and administration at Loyola University New Orleans so I can learn as much about health care law and legal research as possible. Currently, I'm working on ketamine legislation with a trauma surgeon at the local trauma center, and our LA-ACEP leaders are planning to make some good state-level changes in the coming years, so we're hoping to get as many Louisiana physicians involved as possible.

How You Can Get Involved, Too

If you're thinking about getting involved in advocacy work for the first time, the hardest part is getting started. My advice? Just throw yourself in! After my first experience in Louisiana, I spent my 2021 summer taking every advocacy course I could (thanks to virtual education, taking courses is easier than ever). I had a great experience at ACEP's Leadership & Advocacy Conference (acep.org/LAC), where we were trained on proper advocacy skills and met with various senators and representatives. Once I felt more confident, I reached out to my local legislators. I have already met with my state representative and met another one just by putting myself out there, and they were very welcoming. We met for coffee and talked about problems and solutions.

I believe emergency physicians are uniquely qualified as advocates because it's what we do all day, every day. At the end of the day, we have not lost sight of the fact that we all went into medicine to *help* people. Getting involved with advocacy is another way we can help solve problems that affect our patients. As we learned in Louisiana, we can really move the needle when we work together to help make a difference. 🍀

References

1. *Guidelines regarding the role of physician assistants and nurse practitioners in the emergency department*. 2020 June. <https://www.acep.org/globalassets/new-pdfs/policy-statements/guidelines-reg-the-role-of-physician-assistants-and-nurse-practitioners-in-the-ed.pdf>



DR. KUO is a staff physician at Ochsner Health System in New Orleans, Louisiana.

DALVANCE® (dalbavancin) for injection, for intravenous use

PROFESSIONAL BRIEF SUMMARY
 CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

INDICATION AND USAGE
Acute Bacterial Skin and Skin Structure Infections
 DALVANCE® is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-susceptible and methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus anginosus* group (including *S. anginosus*, *S. intermedius*, *S. constellatus*) and *Enterococcus faecalis* (vancomycin susceptible isolates).

Usage
 To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS
 DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
 Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE. If an allergic reaction to DALVANCE occurs, discontinue treatment with DALVANCE and institute appropriate therapy for the allergic reaction. Before using DALVANCE, inquire carefully about previous hypersensitivity reactions to other glycopeptides. Due to the possibility of cross-sensitivity, carefully monitor for signs of hypersensitivity during treatment with DALVANCE in patients with a history of glycopeptide allergy [see Patient Counseling Information].

Infection-Related Reactions
 DALVANCE is administered via intravenous infusion, using a total infusion time of 30 minutes to minimize the risk of infusion-related reactions. Rapid intravenous infusions of DALVANCE can cause flushing of the upper body, urticaria, pruritus, rash, and/or back pain. Stopping or slowing the infusion may result in cessation of these reactions.

Hepatic Effects
 In Phase 2 and 3 clinical trials, more DALVANCE than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN). Overall, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the DALVANCE and comparator arms [see Adverse Reactions].

Clostridioides difficile-Associated Diarrhea
Clostridioides difficile-associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Treatment with antibacterial agents can alter the normal flora of the colon, and may permit overgrowth of *C. difficile*. *C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial use not directed against *C. difficile* should be discontinued, if possible. Appropriate measures such as fluid and electrolyte management, protein supplementation, antibacterial treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Development of Drug-Resistant Bacteria
 Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

ADVERSE REACTIONS
 The following clinically significant adverse reactions are also discussed elsewhere in the labeling:

- Hypersensitivity Reactions [see Warnings and Precautions]
- Infection Related Reactions [see Warnings and Precautions]
- Hepatic Effects [see Warnings and Precautions]
- Clostridioides difficile-associated Diarrhea [see Warnings and Precautions]

Clinical Trials Experience
 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of DALVANCE cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

Clinical Trials Experience in Adult Patients
 Adverse reactions were evaluated for 2473 patients treated with DALVANCE: 1778 patients were treated with DALVANCE in seven Phase 2/3 trials comparing DALVANCE to comparator antibacterial drugs and 695 patients were treated with DALVANCE in one Phase 3 trial comparing DALVANCE single and two-dose regimens. The median age of patients treated with DALVANCE was 48 years, ranging between 16 and 93 years. Patients treated with DALVANCE were predominantly male (59.5%) and White (81.2%).

Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
 Serious adverse reactions occurred in 121/2473 (4.9%) of patients treated with any regimen of DALVANCE. In the Phase 2/3 trials comparing DALVANCE to comparator, serious adverse reactions occurred in 109/1778 (6.1%) of patients in the DALVANCE group and 80/1224 (6.5%) of patients in the comparator group. In a Phase 3 trial comparing DALVANCE single and two-dose regimens, serious adverse reactions occurred in 7/349 (2.0%) of patients in the DALVANCE single dose group and 5/346 (1.4%) of patients in the DALVANCE two-dose group. DALVANCE was discontinued due to an adverse reaction in 64/2473 (2.6%) patients treated with any regimen of DALVANCE. In the Phase 2/3 trials comparing DALVANCE to comparator, DALVANCE was discontinued due to an adverse reaction in 53/1778 (3.0%) of patients in the DALVANCE group and 35/1224 (2.9%) of patients in the comparator group. In a Phase 3 trial comparing DALVANCE single and two-dose regimens, DALVANCE was discontinued due to

an adverse reaction in 6/349 (1.7%) of patients in the DALVANCE single dose group and 5/346 (1.4%) of patients in the DALVANCE two-dose group.

Most Common Adverse Reactions
 The most common adverse reactions in patients treated with DALVANCE in Phase 2/3 trials were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). The median duration of adverse reactions was 3.0 days in patients treated with DALVANCE. In the Phase 2/3 trials comparing DALVANCE to comparator, the median duration of adverse reactions was 3.0 days for patients in the DALVANCE group and 4.0 days in patients in the comparator group. In a Phase 3 trial comparing DALVANCE single and two-dose regimens, the median duration of adverse reactions was 3.0 days for patients in the DALVANCE single and two-dose group.

Table 1 lists selected adverse reactions occurring in 2% or more of patients treated with DALVANCE in Phase 2/3 clinical trials.

Table 1. Selected Adverse Reactions Occurring in ≥ 2% of Patients Receiving DALVANCE in Phase 2/3 Trials (Number (%) of Patients)

Adverse Reactions	DALVANCE (N = 1778)	Comparator* (N = 1224)
Nausea	98 (5.5)	78 (6.4)
Diarrhea	79 (4.4)	72 (5.9)
Headache	83 (4.7)	59 (4.8)
Vomiting	50 (2.8)	37 (3)
Rash	48 (2.7)	30 (2.4)
Pruritus	38 (2.1)	41 (3.3)

* Comparators included linezolid, cefazolin, cephalixin, and vancomycin.

In the Phase 3 trial comparing the single and two-dose regimen of DALVANCE, the adverse reaction that occurred in 2% or more of patients treated with DALVANCE was nausea (3.4%) in the DALVANCE single dose group and 2% in the DALVANCE two-dose group.

The following selected adverse reactions were reported in DALVANCE treated patients at a rate of less than 2% in these clinical trials:
Blood and lymphatic system disorders: anemia, hemorrhagic anemia, leucopenia, neutropenia, thrombocytopenia, petechiae, eosinophilia, thrombocytosis
Gastrointestinal disorders: gastrointestinal hemorrhage, melena, hematochezia, abdominal pain
General disorders and administration site conditions: infusion-related reactions
Hepatobiliary disorders: hepatotoxicity
Immune system disorders: anaphylactic reaction
Infections and infestations: Clostridioides difficile colitis, oral candidiasis, vulvovaginal mycotic infection
Investigations: hepatic transaminases increased, blood alkaline phosphatase increased, international normalized ratio increased, blood lactate dehydrogenase increased, gamma-glutamyl transferase increased
Metabolism and nutrition disorders: hypoglycemia
Nervous system disorders: dizziness
Respiratory, thoracic and mediastinal disorders: bronchospasm
Skin and subcutaneous tissue disorders: rash, pruritus, urticaria
Vascular disorders: flushing, phlebitis, wound hemorrhage, spontaneous hematoma
Alanine Aminotransferase (ALT) Elevations
 Among patients with normal baseline ALT levels treated with DALVANCE 17 (0.8%) had post-baseline ALT elevations greater than 3 times the upper limit of normal (ULN) including five subjects with post-baseline ALT values greater than 10 times ULN. Among patients with normal baseline ALT levels treated with non-DALVANCE comparators 2 (0.2%) had post-baseline ALT elevations greater than 3 times the upper limit of normal. Fifteen of the 17 patients treated with DALVANCE and one comparator patient had underlying conditions which could affect liver enzymes, including chronic viral hepatitis, history of alcohol abuse and metabolic syndrome. In addition, one DALVANCE-treated subject in a Phase 1 trial had post-baseline ALT elevations greater than 20 times ULN. ALT elevations were reversible in all subjects with follow-up assessments. No comparator-treated subject with normal baseline transaminases had post-baseline ALT elevation greater than 10 times ULN.

Clinical Trials Experience in Pediatric Patients
 Adverse reactions were evaluated in one Phase 3 pediatric clinical trial which included 161 pediatric patients from birth to less than 18 years of age with ABSSSI treated with DALVANCE (83 patients treated with a single dose of DALVANCE and 78 patients treated with a two-dose regimen of DALVANCE) and 30 patients treated with comparator agents for a treatment period up to 14 days. The median age of pediatric patients treated with DALVANCE was 9 years, ranging from birth to <18 years. The majority of patients were male (62.3%) and White (89.0%). The safety findings of DALVANCE in pediatric patients were similar to those observed in adults.

Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
 Serious adverse reactions (SARs) occurred in 3/161 (1.9%) of patients treated with DALVANCE, all in the single-dose arm. There were no adverse reactions leading to DALVANCE discontinuation.

Most Common Adverse Reactions
 Most common adverse reaction occurring in more than 1% of pediatric patients 2/161 (1.2%) was pyrexia.

Other Adverse Reactions
 The following selected adverse reactions were reported in DALVANCE-treated patients at a rate of less than 1% in this pediatric clinical trial:
Gastrointestinal disorders: diarrhea
Nervous system disorders: dizziness
Skin and subcutaneous tissue disorders: pruritus

Post Marketing Experience
 The following adverse reaction has been identified during post-approval use of dalbavancin. Because the reaction is reported voluntarily from a population of uncertain size, it is not possible to reliably estimate the frequency or establish a causal relationship to drug exposure.
 General disorders and administration site conditions: Back pain as an infusion-related reaction [see Warnings and Precautions].

DRUG INTERACTIONS
Drug-Laboratory Test Interactions
 Drug-laboratory test interactions have not been reported. DALVANCE at therapeutic concentrations does not artificially prolong prothrombin time (PT) or activated partial thromboplastin time (aPTT).

Drug-Drug Interactions
 No clinical drug-drug interaction studies have been conducted with DALVANCE. There is minimal potential for drug-drug interactions between DALVANCE and cytochrome P450 (CYP450) substrates, inhibitors, or inducers.

USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary
 There are no adequate and well-controlled studies with DALVANCE use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse developmental outcomes.

No treatment-related malformations or embryo-fetal toxicity were observed in pregnant rats or rabbits at clinically relevant exposures of dalbavancin. Treatment of pregnant rats with dalbavancin at 3.5 times the human dose on an exposure basis during early embryonic development and from implantation to the end of lactation resulted in delayed fetal maturation and increased fetal loss, respectively [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data
Animal Data
 No evidence of embryo or fetal toxicity was found in the rat or rabbit at a dose of 15 mg/kg/day (1.2 and 0.7 times the human dose on an exposure basis, respectively). Delayed fetal maturation was observed in the rat at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis).

In a rat prenatal and postnatal development study, increased embryo lethality and increased offspring deaths during the first week post-partum were observed at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis).

Lactation
Risk Summary
 There are no data on the presence of dalbavancin or its metabolite in human milk, the effects on the breast-fed child, or the effects on milk production. Dalbavancin is excreted in the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DALVANCE and any potential adverse effects on the breast-fed child from DALVANCE or from the underlying maternal condition.

Pediatric Use
 The safety and effectiveness of DALVANCE for the treatment of ABSSSI has been established in pediatric patients aged birth to less than 18 years. Use of DALVANCE for this indication is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged birth to less than 18 years [see Adverse Reactions].

There is insufficient information to recommend dosage adjustment for pediatric patients with ABSSSI and CLcr less than 30 mL/min/1.73m².

Geriatric Use
 Of the 2473 patients treated with DALVANCE in Phase 2 and 3 clinical trials, 403 patients (16.3%) were 65 years of age or older. The efficacy and tolerability of DALVANCE were similar to comparator regardless of age. The pharmacokinetics of DALVANCE was not significantly altered with age; therefore, no dosage adjustment is necessary based on age alone.

DALVANCE is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dosage selection in this age group.

Renal Impairment
 In patients with renal impairment whose known CLcr is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended regimen for DALVANCE is 1125 mg, administered as a single dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis. There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years with CLcr less than 30 mL/min/1.73m².

Hepatic Impairment
 No dosage adjustment of DALVANCE is recommended for patients with mild hepatic impairment (Child-Pugh Class A). Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients.


OVERDOSAGE
 Specific information is not available on the treatment of overdose with DALVANCE, as dose-limiting toxicity has not been observed in clinical studies. In Phase 1 studies, healthy volunteers have been administered cumulative doses of up to 4500 mg over a period of up to 8 weeks (not an approved dosing regimen), with no signs of toxicity or laboratory results of clinical concern.

Treatment of overdose with DALVANCE should consist of observation and general supportive measures. Although no information is available specifically regarding the use of hemodialysis to treat overdose, in a Phase 1 study in patients with renal impairment less than 6% of the recommended dalbavancin dose was removed.

Distributed by:
 Allergan USA, Inc.
 Madison, NJ 07940

Patented. See www.allergan.com/patents.
 DALVANCE® is a registered trademark of Allergan Pharmaceuticals International Limited.
 © 2021 Allergan. All rights reserved.
 Ref: v2.0USP0100 Revised: 7-2021
 US-DAV-210121 MASTER

US-DAV-210199



A FEW FOUNDERS OF EMERGENCY MEDICINE, CLOCKWISE FROM TOP LEFT: Dr. John G. Wiegenstein (1930–2004); Dr. George Podgorny (1934–2013); Dr. Peter Rosen (1935–2019); and an illustration of Dr. Ronald L. Krome (1936–2013).

PHOTOS: ACEP

WE DISSENT

HOW THE ACT OF DISSENT IS AN IMPORTANT AND PROUD TRADITION WITHIN OUR SPECIALTY

by GARY GADDIS, MD, PHD, FACEP, FIFEM

The Oxford English Dictionary defines *dissent* as, “the expression or holding of opinions at variance with those previously, commonly, or officially held.”

Emergency medicine, perhaps more than any other medical specialty, is a specialty borne of dissent. I believe younger emergency physicians need to know this history. Reasoned dissent was a crucial tool in the formation of emergency medicine, and it continues to improve our practice environment today.

How Dissent Can Change the World

From a global perspective, those who dissent have improved nations. Consider Dr. Martin Luther King Jr., who is honored not for “putting up” silently with our society’s flaws but for his leadership in the Civil Rights movement, which implemented thoughtful, non-violent dissent against laws and barriers that precluded the full benefits of citizenship from being enjoyed by all Americans. Also, consider the legacy of the late Supreme Court Justice Ruth Bader Ginsburg. She regularly implemented dissent in her writings and decisions during her long and illustrious career on the bench.

In considering these legacies, it is also appropriate to review the influence dissent has on emergency medicine as a specialty.

1. The Founding of ACEP

The founding of the American College of

Emergency Physicians can be considered an act of dissent. ACEP was founded 11 years before the American Board of Medical Specialties (ABMS) granted emergency medicine official specialty status in 1979. Physicians, linked by a dissenting vision that “emergency room medicine” could indeed become a career choice, met in Arlington, Virginia, in November 1968. At the time, emergency medicine had no identifiable special body of knowledge and was widely considered a place for doctors who had challenges with other practices. ACEP’s founders had an initial goal of sharing ideas to improve business practices and foster new educational programs.

At that meeting, Dr. R. R. Hannas took dissent a step further. He articulated a unique vision for emergency medicine to become a full-fledged medical and academic specialty, which our nation demonstrably needed. Did you know that in 1966, two years before ACEP was founded, the National Academy of Sciences disseminated a white paper titled *Accidental Death and Disability: The Neglected Disease of Modern Society*?¹ This work highlighted broad deficiencies in America’s emergency care systems. Dr. Hannas’ new vision provided a road map to illustrate a path for remediating many of those deficiencies.

2. Dr. Bruce Janiak, the World’s First Emergency Medicine Resident

Nearly simultaneously, the world’s first emergency medicine resident, Dr. Bruce Janiak, began training in 1969 at the University of Cin-

cinnati. At that time, there was no such thing as an academic emergency department or an emergency medicine residency program. Dr. Janiak rotated on various relevant services as he developed his own personalized curriculum, such as it was, on the fly. He spent two years training for a specialty for which there would not be an official certifying board until 1979.

Dr. Janiak was so confident in his dissenting vision that while in his residency, he said if he were a betting man, he “wouldn’t bet against me.” This statement was noted within the exhibits commemorating ACEP’s 50th anniversary, displayed at the 2018 ACEP Scientific Assembly in San Diego. Time has certainly proven Dr. Janiak to be right.

3. Laboring in Dissent

Organized dissent by many explains how emergency medicine became an official specialty within ABMS. ABMS voted in September 1977 (100 to five) to reject emergency medicine’s application for specialty board status. Not content to accept failure, numerous visionary founders of our specialty, such as Drs. John Wiegenstein, George Podgorny, David Wagner and Ron Krome, led the efforts to labor effectively in dissent. Two years later in September 1979, through their considerable and persuasive efforts, emergency medicine became an approved specialty by ABMS in an almost unanimous vote. It is difficult to capture in a brief paragraph the extensive persuasive efforts required to effect this change. These leaders dissented from the overwhelming opinion of the ABMS, as expressed in 1977. They dissented so effec-

tively that they changed minds and hearts and made emergency medicine an official ABMS-recognized specialty in 1979.

Further, we all have heard of Dr. Peter Rosen, a founder of our specialty. I will paraphrase an incident involving Dr. Rosen, as reported by Dr. Brian Zink in his book, *Anyone, Anything, Anytime: A History of Emergency Medicine*. Dr. Zink interviewed Dr. Rosen in Jackson, Wyoming, in 2003 as he collected the history of our specialty “from the horses’ mouths,” as it were.

In 1977, Dr. Rosen was leading the emergency department at the University of Chicago, and he had the occasion to meet with his new dean. The dean, Daniel C. Tosteson, was an anatomist and not a physician. The dean opined in meeting with Dr. Rosen that he did not understand why emergency medicine should exist because there is no “biology” of emergency medicine. (We don’t claim an organ system in the manner of nephrologists with the renal system or cardiologists with the cardiovascular system.) The dean noted that if he were to have a heart attack, for example, he wanted to receive the care of a cardiologist. Dr. Rosen asked this dean how he might know he was having a heart attack. The dean replied that he’d expect to be having chest pain. Dr. Rosen replied by asking what the dean would expect to occur if the symptoms were mainly nausea. Dr. Rosen was quoted by Dr. Zink as saying, regarding the reaction of Dr. Tosteson, “It was the first time it had ever occurred to him that maybe you couldn’t run an emergency department with 47 different specialties. ... I got so pissed at him that ... I went out and

By the Numbers

CURRENT SPECIALTY STATISTICS

IN 2020

48,835

clinically active
emergency physicians

MEDIAN AGE

50

28%

WOMEN

EMERGENCY PHYSICIANS

14.9

per 100,000 population

EMERGENCY PHYSICIANS

92%

Work in urban areas

EMERGENCY PHYSICIANS BY RACE

WHITE	64.6%
ASIAN	18.6%
HISPANIC OR LATINO	9.2%
BLACK OR AFRICAN AMERICAN	4.9%
UNKNOWN	2.6%
AMERICAN INDIAN AND ALASKA NATIVE	0.1%

SOURCE: Annals of Emergency Medicine/Zippia



ABMS Assembly unanimously approved the ABEM application for primary board status on September 22, 1989. Top Row (L-R) Ronald L. Krome, M.D.; G. Richard Braen, M.D.; Gail V. Anderson, M.D.; Benson S. Munger, Ph.D.; Joseph E. Clinton, M.D.; George Podgorny, M.D.; David K. Wagner, M.D.; Harvey W. Meislin, M.D. Bottom Row (L-R) Judith E. Tintinalli, M.D.; Mary Ann Reinhart, Ph.D.; Michael V. Vance, M.D.; Susan K. Adsit.

wrote a paper.” Now, *that’s* effective dissent, when you look your dean in the eye and use his own words to explain why his opinion of our specialty is so wrong!

4. IV Opiate Analgesia Administration

Consider how we now employ opiate analgesia for patients with abdominal pain. When I finished residency in 1989, such a practice by emergency physicians was considered wildly inappropriate. Merciful IV opiate analgesia could be administered only after a surgeon (typically one who was often a surgical resident with less experience than the emergency department attending) had operated on or first seen and laid hands on the patient. The dogma of Dr. Zachary Cope, which had persisted since the early decades of the 20th century, was rejected once emergency medicine researchers dissented with data in peer-reviewed publications. If you wish to read more about how Dr. Cope and his dogma regarding analgesia became a historical footnote, peruse the online tool The NNT at www.thennt.com/nnt/opiate-analgesia-acute-abdominal-pain/. It summarizes the body of research that led to our modern view regarding use of analgesia for patients with acute abdominal pain.

5. Overturning “Pain as the Fifth Vital Sign”

More recently, emergency physicians have been among those speaking out against the Pain as the Fifth Vital Sign (PATFVS) initiative. The Joint Commission for Accreditation of Hospital Organizations, now known as The Joint Commission, initiated PATFVS in 2000. Of course, pain is a symptom and not a sign, so the entire initiative was flawed from the outset. Emergency physicians have been among many within the medical field to

“When we engage in dissent in the interest of more effective emergency department care, we not only foster team building and improved patient care environments, we add our names to the long, honorable and growing register of change agents who have utilized constructive dissent to advance our specialty.”

call out the folly. Joint Commission was only supported by a letter to the editor in the *New England Journal of Medicine* stating that opiates, such as oxycodone and hydrocodone, were not potentially addictive.² Emergency medicine researchers are among those who have demonstrated how the opiate crisis has followed increased prescribing of opiates, a practice that was arguably augmented by concomitant patient satisfaction initiatives. Fortunately, The Joint Commission finally heeded dissent from ACEP and others and overturned its advocacy for PATFVS. Efforts within The Joint Commission to change its standards began in 2016 and were finally officially revised by 2018.³

Dissent Fosters Growth and Improvement

These examples demonstrate how reasoned dissent has led to positive changes. I hope they can inspire some of you to dissent thoughtfully and constructively from the status quo when it becomes necessary. As you do, realize that you are the latest in a long line of emergency physicians who are not content to put up and shut up when you know that changes are needed to improve the safety or efficacy of the systems that deliver lifesaving care to our patients.

When we engage in dissent in the interest of more effective emergency department care, we not only foster team building and improved patient care environments, we add our names to the long, honorable and growing register of change agents who have utilized constructive dissent to advance our specialty. Sometimes, those in leadership require time to become convinced of the merits of our suggestions, but persistent reasoned dissent is part of the fabric of an aware and caring emergency physician. ➔

References

1. National Academy of Sciences (US) and National Research Council (US) Committee on Trauma; ssNational Academy of Sciences (US) and National Research Council (US) Committee on Shock, Accidental Death and Disability: The Neglected Disease of Modern Society. Washington (DC): National Academies Press (US). 1966. <https://www.ncbi.nlm.nih.gov/books/NBK222962/?report=classic>
2. Porter J, Jick H. Addiction rare in patients treated with narcotics. *N Engl J Med*. 1980;302(2):123
3. Baker DW. The Joint Commission’s pain standards: origins and evolution. 2017 May. https://www.jointcommission.org/-/media/tjc/documents/resources/pain-management/pain_std_history_web_version_05122017.pdf.pdf.



DR. GADDIS is professor of emergency medicine at Washington University School of Medicine in St. Louis, MO.



EIGHTYONECONZ

(R-L) Dr. Radecki hiking with his family, Alexander, Annie, and Lydia in Christchurch, New Zealand.

Going Global

by CEDRIC DARK, MD, MPH, FACEP, MEIC

A series about health care systems and the practice of emergency medicine across the world

In this series, we're going to talk about various countries and how they compare to the United States as representative prototypes to structure and finance care; the first of these prototypes, as described in the book, *The Healing of America* by T.R. Reid, is the National Health System model.

In the United States, we have our own version of this prototype called the Veterans Affairs (VA), where essentially, if you work for the VA, whether you are employed directly by the federal government or your group is under contract with them, you're essentially acting as an *agent* of the federal government delivering care to veterans. The hospitals and clinics are all owned by the government. And the financing is typically through broad-based taxation. There are several countries that do this; England, Spain, and Italy are prime examples.

New Zealand is also a country that utilizes a National Health System structure. It is a publicly funded system, administered through 20 different regional authorities, which began in 1938 with the passage of their Social Security Act. The New Zealand system includes benefits like inpatient care, outpatient care, mental health, long-term care, prescription drugs, maternity, physical therapy, medical equipment,

home health, and hospice. It doesn't include benefits like adult dental care, eye care, and orthodontics.

New Zealand's system is financed mostly by taxes with the national government setting an annual budget and a benefits package. Patients do have some copays, which seem to be small, maybe \$10 to \$34 USD, on average. And they do all of this for only 9 percent of GDP, which is about half of what we spend in the United States on our health care system in terms of our percentage of GDP.

I spoke with Ryan Radecki, MD, FACEP, the author of "Pearls from the Medical Literature" column, because after spending many years in the United States, he is currently living and practicing in New Zealand.

Does New Zealand have similar challenges regarding getting follow-up care for your patients or making sure they can get access to medications or access to specialists, like we do in the United States?

Dr. Ryan Radecki: Access to primary care has traditionally been something that's one of New Zealand's strengths. It's been very easy to get access to primary care for either routine checkups or urgent visits or hospital follow-up. It's a little more challenging as of late because the borders have been closed and it's been a little bit harder to access some of the

World TravelERs: New Zealand

specialists and medical resources that New Zealand depends upon from overseas. Interestingly, about 20 percent to 30 percent of their physician workforce is born overseas, so they really do depend on foreign trained doctors as the foundation of their healthcare system.

New Zealand has all the same medications that the United States has as far as the basic [ones]. There's absolutely no trouble getting access to a specialist—at least in the hospital/acute care setting—to perform emergency surgery, acute intervention, interventional radiology, or anything else the patient needs at this particular tertiary hospital that I work at. However, there is, I think, one dermatologist for the entire South Island. So, if a patient is trying to see a dermatology specialist in the publicly funded health care system, they can end up with some pretty long wait times.

Before moving to New Zealand, you worked at a public hospital system in Houston, Texas. If you're trying to consider how hard it is to see the dermatologist in New Zealand versus the public hospital system in the United States, is it harder, easier, or about the same?

Dr. Radecki: I'd probably say it's very similar. And the difference being that most people in the United States don't access the public health care system for their health care needs. Also, about a third of the people in New Zealand

also buy a private healthcare insurance policy that allows them more rapid access to some of these specialists (like dermatology) or decreased wait times on some of their elective procedures.

Speaking of the wait times on elective procedures, how would you say they typically compare to what you would see in the United States?

Dr. Radecki: Again, I think it all depends. Hip replacements or knee replacements take time. Elective cholecystectomies, these things take time in New Zealand. Certainly, it's nothing like the private system in the United States, where if you had a little bit of a biliary colic and you go to the emergency department, you might have your gallbladder taken out that day.

Would you say medications are also cheap in New Zealand, too?

Dr. Radecki: When you write a patient a prescription, their co-pay is quite small. And then if you have a specific type of community services card or if you're in a lower socioeconomic income bracket, then obviously it's even closer to free. The New Zealand Formulary determines what the public system covers. So there are a limited list of medications I can prescribe. But then again, you don't need ac-

cess to every different iteration of ACE inhibitor, for example.

Some things make sense, like [limited availability of] boutique cancer drugs, but some of things are a little bit more controversial, like these SGLT2 inhibitors for diabetes, which are fairly common and pervasive in the United States. These are *just* getting approved in New Zealand right now through a cost/benefit discussion, because they do end up on the more expensive side of things, but they also have well demonstrated cardiac benefits.

For the most part, 99 percent of the things that emergency physicians would see on a regular basis are also seen here in New Zealand.

As an emergency physician, do you feel there's any medication you wish you had over there that you don't have access to?

Dr. Radecki: They don't have Ketorolac. They do rectal diclofenac as their alternative for intramuscular ketorolac for renal colic. They have a solution for everything. It's just not the solution that you're used to in the United States.

What has your experience been as a patient in the health care system?

Dr. Radecki: We've accessed the outpatient GP system, just for before school checks for our kids. There's a dental service that comes around to all the schools and does dental checks on all the kids and refers anybody for a specific dental follow-up if they need additional cleaning or treatments, and that's all free and publicly funded as well. And then my family members—who have tried to access the system—have had no trouble getting appointments and no trouble getting the procedures and tests that they needed, and we've had our results in a timely fashion. We haven't run up against any delays accessing our health care through the public system.

What is the greatest lesson you've learned that might inform people back

home, listeners, or maybe even policy makers, on how we could restructure our health care system in the United States?

Dr. Radecki: I think the most obvious value or endorsement of universal health care is that it's publicly-funded, regionally administered, and [delivered by] 20 different regional authorities. People [here] are advocating to move the United States to one of these publicly funded models, but nobody is saying, "*Let's tear that up and leave some of our population uncovered and switch the United States model.*"

In New Zealand, it blows their mind that the United States cannot somehow all get together and fix the system. The thought of medical bankruptcy, that you might run out of money, that you might lose your health insurance because you've lost your job, is just insane to them. And that people who are effectively in their greatest hour of need, whose families are suffering the most, have to have that suffering compounded by the issues with the health care system.

Is there anything else you want to tell our readers about New Zealand?

Dr. Radecki: It's a great place to work and it's probably the most fun I've had practicing medicine in a long time. And I think that, certainly, it's a lot more fun than practicing medicine in the United States over this past year. I encourage everyone to come visit once the borders are open. It's just lovely. 🇳🇿


Listen to our full conversation at EM:RAP



THE ART IN MEDICINE

Cara Borelli, DO, ACEP Now Resident Fellow, recently interviewed Katrina Lettang, MD, for this month's Resident Voice video. Dr. Lettang shares her experience working with various art mediums as a way to share personal experiences as an emergency physician through art. One painting features human blood to try and capture the duality of something doctors see every day.

Watch the full interview to see Dr. Lettang's paintings. 🎨



"Blood & Ink" by Dr. Katrina Lettang and Dr. David Bell

Safer Together

Your team working with ours – that's Safer Together.

Reveal your team's potential for continued process and quality improvement in the care of patients with suspected cardiac emergencies, partner with ACC for Chest Pain Center Accreditation.

Pair with **Chest Pain – MI Registry™** for LOW-RISK/NSTE-ACS/STEMI data reporting

Contact us at **800-257-4739** or **accreditationinfo@acc.org** to learn more.

Accreditation.ACC.org

AMERICAN COLLEGE of CARDIOLOGY®

©2022 American College of Cardiology R22029

ACEP4U: Multiply Your Impact

ACEP COMMITTEES ARE A WAY TO COMBINE FORCES WITH YOUR PEERS TO MAKE A BIGGER DIFFERENCE

by JORDAN GRANTHAM

ACEP members often wonder how they can get more involved with the work of the College, especially when it comes to their niche interests or passion projects—clinical topics, advocacy issues, career development, etc. One way to take your involvement to the next level is to get involved with ACEP committees and sections, but this article will focus on committee involvement. If you've ever thought about contributing to an ACEP committee, now is the time to do it. Applications are now being accepted through May 15 on our website, acep.org/committee-involvement.

What's the Difference Between ACEP Committees and Sections?

ACEP committees are work groups appointed by ACEP's President-Elect. Committees are assigned objectives through the Board related to the work of the College, including the implementation of Council resolutions. There are 31 committees tackling a broad variety of issues. (See sidebar for the full list.)

ACEP sections have a different structure. ACEP members can elect to join any of ACEP's 40 sections, so many sections are much bigger than committees. Section membership is a way to network and share information with like-minded peers under the umbrella of specific topics within emergency medicine (EM). Section members who want to go beyond the networking aspect to help set the agenda and goals of the section can get further involved by running for section officer positions. Learn more at acep.org/sections.

What Type of Projects Do ACEP Committees Work On?

ACEP committees tackle big topics every year, developing policy statement and other resources to fill gaps and help ACEP members. Here are a few highlights from recent committee efforts:

- The **Research Committee** oversees ACEP's annual Research Forum (RF), including the special edition COVID-19 specific forum hosted in 2021. Many of the 2021 RF abstracts are now available on-demand in the ACEP Online Learning Collaborative, and abstracts are now being accepted for the 2022 Research Forum (acep.org/RF).
- The **Clinical Policies Committee** completed new clinical policies related to community-acquired pneumonia and opioids and is working on policies related to appendicitis, acute heart failure syndromes, and mild traumatic brain injury (acep.org/clinicalpolicies). Revisions to the stroke, sedation, airway management, blunt trauma, pediatric fever, and seizures clinical policies are underway.
- The **Federal Government Affairs Committee** recently helped ACEP's advocacy team finalize its legislative and regulatory priorities for the 117th Congress, 2nd ses-

sion. (See page 3 for more details.)

- The **Reimbursement and Coding & Nomenclature Advisory** maintain detailed reimbursement FAQs on the ACEP website, and they have just updated them to reflect 2022 changes at acep.org/reimbursement-faqs. The last physician fee schedule included some complicated but very important policies, and the new FAQs help ACEP members navigate the changes.
- The **Academic Affairs Committee** organizes ACEP's popular Virtual Grand Rounds educational events (acep.org/virtualgrandrounds). ACEP members have free access to the live webinars, and the past 17 VGRs are available for on-demand viewing. This committee also recently updated the policy statement "Overcoming Barriers to Promotion of Women and Underrepresented in Medicine (URiM) Faculty in Academic Emergency Medicine," now available at acep.org/policystatements, along with a Policy Resource and Education Paper (PREP) by the same title.
- The **Health Information Technology Committee** developed resources to help emergency physicians navigate the "Open Notes" provision in the 21st Century Cares Act, which made ED notes visible to patients via the electronic health record portal (acep.org/healthinfotech). (See page 1 for more details.)
- The **EM Practice Committee** revised ACEP's policy statements to strengthen EM scope of practice. Those statements are part of ACEP's expanded Career Center (acep.org/careercenter).
- The **Quality & Patient Safety Committee** and the **CEDR Committee** are heavily involved in the field-testing process for the first EM-specific episode-based cost measure. The committees are reviewing field-testing reports and providing feedback to Acumen, a contractor of the Centers for Medicare & Medicaid Services (CMS), regarding the potential use of this cost measure in the Merit-based Incentive Payment System (MIPS).
- The **Communications Committee** works with ACEP's public relations team to fulfill media requests on various topics as part of its efforts to educate the public about the value of emergency physicians. It assisted with a recent bilingual media tour focused on combatting vaccine hesitancy.
- The **Medical-Legal Committee** produced a six-part webinar series about EMTALA to help ACEP members better understand the law, how it is enforced and how it affects daily practice (acep.org/emtala-webinars).
This is only a small sampling of the way ACEP committees are working year-round to support emergency physicians.
Learn more about how you can get involved and make an even bigger difference at acep.org/committees. 📍



Laura Oh, MD, FACEP, chair of ACEP's Academic Affairs Committee, leads the group's meeting during ACEP21 in Boston.



Matthew Gangidine, MD, presents his research as part of the Brooks F. Bock Lecture and Abstract Session during the ACEP21 Research Forum in Boston. The annual Research Forum is organized by ACEP's Research Committee, and abstracts for the 2022 event are being accepted through May 18 at acep.org/RF.

ACEP Committees

Please consider getting involved as a member of an ACEP committee! Apply at acep.org/committee-involvement by May 15 for consideration for the upcoming cycle.

- » Academic Affairs
- » Audit
- » Awards
- » Bylaws
- » Bylaws Interpretation
- » Clinical Emergency Data Registry
- » Clinical Policies
- » Clinical Resources Review
- » Coding & Nomenclature Advisory
- » Communications
- » Compensation
- » Disaster Preparedness & Response
- » Education
- » EMS
- » EM Practice
- » Ethics
- » Federal Government Affairs
- » Finance
- » Health Information Technology
- » International Emergency Medicine
- » Medical-Legal
- » Membership
- » National Chapter Relations
- » Pediatric EM
- » Public Health & Injury Prevention
- » Quality & Patient Safety
- » Reimbursement
- » Research
- » State Legislative/Regulatory
- » Well-Being

DOGMA FEELS RIGHT UNTIL YOU STEP IN IT

SKEPTICS' GUIDE TO EMERGENCY MEDICINE



DR. MILNE is chief of emergency medicine and chief of staff at South Huron Hospital, Ontario, Canada. He is on the Best Evidence in Emergency Medicine faculty and is creator of the knowledge translation project the Skeptics' Guide to Emergency Medicine (www.TheSGEM.com).

Go Big or Go Small?


Is there a difference between the types of catheter used in hemodynamically stable patients?

by KEN MILNE, MD

Case: A 54-year-old male presents to your emergency department the day after being involved in a snowmobile accident on the weekend. He reports he was riding his sled along an embankment when it rolled. He thought it would get better, but the chest pain and shortness of breath have gotten worse over the past 48 hours. His vital signs are normal, and the physical exam indicates he has bruising and tenderness over the left chest wall, with diminished left-sided lung sounds. A CT scan reveals three rib fractures and a hemothorax estimated to measure 600 cc, with no additional injuries.

Clinical Question: Are small pigtail catheters (PCs) as effective as large-bore chest tubes (LBCTs) for the treatment of hemodynamically stable patients with traumatic hemothorax?

Background: Traumatic hemothoraces have been traditionally treated with LBCTs. It



CHRIS WHISEN & SHUTTERSTOCK.COM

CONTINUED on page 16

Remember to respect the triangle of safety.

ACEP SIM TRAINING COURSE

Advance Your Skills Through Hands-On Training in an Immersive and Risk-free Simulation Center

Space is limited and in high demand

Register Today! • acep.org/sim

May 23-25, 2022 | Tampa, FL
at the Center for Advanced Medical Learning and Simulation (CAMLS)

American College of Emergency Physicians®
ADVANCING EMERGENCY CARE

Approved for AMA PRA Category 1 Credit™

3-year accreditation term

Become an Accredited Geriatric Emergency Department Today

Apply for ACEP's geriatric ED accreditation program and validate your hospital's commitment to:

- Providing a more positive and sensitive physical environment
- Adopting standardized approaches to geriatric care
- Ensuring optimal transitions of care from the ED to other settings such as inpatient, home, community-based care, rehabilitation or long-term care
- Supporting geriatric-focused quality improvement

Geriatric EDs promote best clinical practices for older adults and have the potential to improve health outcomes, coordinate care more effectively, and reduce cost of care.

ACEP Geriatric Emergency Department Accreditation

American College of Emergency Physicians®
ADVANCING EMERGENCY CARE

Join the 300+ global Emergency Departments that have received GED accreditation

ACEP.org/GEDA

is important to place these in the pleural space and in the zone of safety. Whether the tube is directed up or down does not seem to be associated with outcomes.¹

A small observational study looked at 36 patients with traumatic hemothorax or hemopneumothorax receiving a PC and compared them to 191 patients receiving a LBCT. The small catheter seemed to work just as well as the LBCT.²

Reference: Kulvatunyou N, Bauman ZM, Edine SBZ, et al. The small (14 Fr) percutaneous catheter (P-CAT) versus large (28–32 Fr) open chest tube for traumatic hemothorax: a

multicenter randomized clinical trial. *J Trauma and Acute Care Surg.* 2021;91(5):809-813.

- **Population:** Hemodynamically stable adult patients 18 years or older suffering traumatic hemothorax or hemopneumothorax requiring drainage at the discretion of the treating physician
 - » **Exclusions:** Emergent indication, hemodynamic instability, patient refuses to participate, prisoner or pregnancy
- **Intervention:** Small (14 Fr) pigtail catheter
- **Comparison:** Large (28–32 Fr) large-bore

- chest tube
- **Outcome:**
 - » **Primary Outcome:** Failure rate defined as radiographically apparent hemothorax after tube placement requiring an additional intervention, such as second tube placement, thrombolysis or video-assisted thoracoscopic surgery
 - » **Secondary Outcomes:** Insertion complication rate; drainage output (30 minutes, 24-hour, 48-hour and 72-hour); hospital course outcome up to 30 days (total tube days, ICU length of

stay, hospital length of stay and ventilator days); and insertion perception experience (IPE) score (1–5 subjective score, with 1 meaning “it was okay” to 5 meaning “it was the worst experience of my life”)

- **Trial Design:** Multicenter, noninferior, unblinded, randomized, parallel assignment comparison trial
- Authors’ Conclusions:** “Small caliber 14-Fr PCs are equally as effective as 28- to 32-Fr chest tubes in their ability to drain traumatic HTX with no difference in complications. Patients reported better IPE scores with PCs over chest tubes, suggesting that PCs are better tolerated.”


Results: They identified 222 eligible patients over five years, with 119 (56 PC and 63 LBCT) included in the final cohort. The mean age was 55 years, 82 percent were male, 81 percent had blunt trauma and median time to tube placement was one to two days after injury.

Key Result: Pigtail catheters were noninferior to large-bore chest tubes for treating traumatic hemothorax and hemopneumothorax.

- **Primary Outcome:** Failure rate was 11 percent for PC versus 13 percent for LBCT ($P=0.74$).
- **Secondary Outcomes:** There were two insertion-related complications, one from each group (bleeding from PC necessitated a thorotomy, and extra pleural position from chest tube placement required another tube placement). There were two deaths, one from each group (PC group had a PE on postinjury day 10 and the tube had already been removed, and LBCT group had a nontrauma-related death at an outside institution). There was no statistical difference between PC and LBCT in terms of drainage tube output except at 30 minutes, with more in the PC group. There was no statistical difference in hospital course. Patients reported better IPE scores in the PC group compared to the LBCT group.

EBM Commentary:

1. **Selection Bias:** There were 102 patients excluded from the 222 eligible. Twenty-seven of the exclusions were for “MD preference.” This could have introduced some selection bias into the trial.
2. **Unstable Patients:** Hemodynamically unstable trauma patients were also excluded from this trial. Open thoracostomy and the placement of a LBCT is still considered by many to be the primary treatment for the evacuation of hemothorax in the hemodynamically unstable trauma patient. The exclusion of hemodynamically unstable patients could also explain the lower-than-anticipated failure rate, which is discussed below. Further research will be needed to determine if PC catheters are noninferior to LBCTs in hemodynamically unstable trauma patients.
3. **Patient-Oriented Outcome:** Tube failure rate seems like a disease-oriented outcome (DOO). The IPE score seems like a more patient-oriented outcome (POO). Patients did prefer the PC compared to the LBCT. However, the IPE scale developed by the investigators has not been externally validated.
4. **Low Overall Failure Rates:** The failure rates in this study were 11 percent and 13 percent for PCs and LBCTs, respectively.



Clinician

“A fast result helps prevent transmission and expedite partner treatment.”

Patient

“Fast information helps protect me and my partner.”

Minutes Matter
Test, Talk, Treat in one visit



- ✓ **Accurate**
PCR. 97% accuracy or greater. See our Instructions for Use for details.
- ✓ **Fast**
Results in 28 minutes, while the patient is present.

- ✓ **Easy to use**
CLIA-waived and designed for the point of care.
- ✓ **Flexible**
No extra instrument for optimal surge capacity.



LEARN MORE

1-833-GoVisby (1-833-468-4729)
sales@visbymedical.com
www.visbymedical.com

Visby Medical Sexual Health Click Test

— For self-collected vaginal swabs —



This device has received 510(k) clearance by the FDA and granted a CLIA waiver. Photos are stock photos, used for illustrative purposes only. Posed by models.

PL-000139 Rev A

TOXICOLOGY Q&A



JASON HACK (CLEANDER PHOTOGRAPHY)

Purity & Poison

by JASON HACK, MD

Question: Often associated with royal families, which delicate flower symbolizing purity and humility can cause cardiac arrest if handled incorrectly?

ANSWER on page 19

These figures are significantly lower than the rate of 28.7 percent reported in a recent multi-institutional study from the Eastern Association for the Surgery of Trauma (EAST). This may be because the study excluded patients in extremis, as the authors point out in the discussion. However, the study population in this trial had a mean hemothorax volume of 612 mL versus 191 mL is the EAST study. This indicates that volume of blood did not appear to influence rate of failure compared to what has been published elsewhere.³

5. **Stopped Early:** This trial was stopped before reaching its goal of 190 patients, despite enrolling at four sites for five years. The authors reported slow enrollment and disruption to research caused by the COVID-19 pandemic. They did conduct an interim analysis prior to stopping enrollment, and their primary endpoint still met the prespecified noninferior margin.

SGEM Bottom Line: Offering a pigtail catheter instead of a large-bore chest tube for the evacuation of a traumatic hemothorax in a hemodynamically stable patient is reasonable.

Case Resolution: The patient is offered the traditional LBCT or the pigtail. He decides to go with the small catheter, which is placed without any complications. He is admitted to the trauma service for pain management and monitoring. The PC is removed on day three of hospitalization, and he is discharged on day five.

Thank you to Dr. Chris Root, a second-year resident physician in the Department of Emergency Medicine at the University of New Mexico Health Sciences Center in Albuquerque, New Mexico, for his help with this review.

Remember to be skeptical of anything you learn, even if you heard it on the Skeptics' Guide to Emergency Medicine. 📌

References


1. Benins MV, Egger ME, Harbrecht BG, et al. Does chest tube location matter? An analysis of chest tube position and the need for secondary interventions. *J Trauma Acute Care Surg.* 2015;78(2):386-390.
2. Kulvatunyou N, Joseph B, Friese RS, et al. 14 French pigtail catheters placed by surgeons to drain blood on trauma patients: is 14-Fr too small? *J Trauma Acute Care Surg.* 2012;73(6):1423-1427.
3. Prakash PS, Moore SA, Rezende-Neto JB, et al. Predictors of retained hemothorax in trauma: results of an Eastern Association for the Surgery of Trauma multi-institutional trial. *J Trauma Acute Care Surg.* 2020;89(4):679-685.

REGISTER TODAY FOR EDDA PHASE I

Are You a Current Director or Aspiring To Be One?

Begin Your Journey with Phase I

April 4 - May 31, 2022
Multiple Online Sessions



This phase is designed to lay the groundwork for your success throughout the Academy with a series of courses on topics you need to know as ED Director. Register now and begin your journey with these interactive small group online sessions.

Phase I Schedule is available online at: acep.org/edda/phase1/schedule

Register Today at acep.org/edda



Approved for AMA PRA Category 1 Credit™

ACN_0322_MC1540_0222

DIGITAL TRANSFORMATION

Quality Driven Emergency Care



ADVANCING EMERGENCY CARE



Meet your administrative & financial requirements with this CMS-designated Qualified Data Registry



Discover low-burden, high-impact, evidence-based best practices in this virtual learning community



Reduce clinician burden with quality measures linked to meaningful outcomes for clinicians & patients



Gain comprehensive insights into emergency medicine research, operations, policy & education



Learn about ACEP's leadership in informatics, electronic health record use optimization & clinician burden reduction

Learn more at acep.org/quality

ACN_0322_MC1545_0222



DR. BORELLI is an emergency medicine resident at the University of Texas Health San Antonio and ACEP Now resident fellow.

Resident Innovations in Medicine

Inspiration can take many different forms

by CARA BORELLI, DO

For this month's "Resident Voice" column, I explore how emergency medicine residents are innovating the field of medicine in creative and diverse ways. I requested residents to submit descriptions of their innovations, and was enthused at the breadth of initiatives being undertaken by emergency medicine residents across the country. I hope these three different initiatives which encompass research, community outreach, and technologic innovations will inspire you to pursue your own innovations.

Starting a Nonprofit Organization

SANDRA COKER, MD, PGY2, University of Chicago

My journey into medicine and to the founding of Black Girl White Coat surprisingly share a few things in common. I was the first in my family to pursue a career as an emergency physician, and I was also the first person I knew who had the audacity to start a nonprofit in the middle of it all. To be honest, I had no idea what to do, how to do it, or where to start with either endeavor. If we are being even more honest, I doubt I would have made it through undergraduate, medical school, and the nonprofit startup process if not for Google.



Dr. Coker

Despite my lack of experience and outside guidance, I always understood the incredible lack of people who looked like me doing the same jobs of which I dreamt.

My sole intention in founding Black Girl White Coat prior to beginning medical school in 2016 was to help provide resources and tools to Black students who either did not have the privilege of physician parents, resources to make their dreams come true, or the knowledge base to even get started. Studying human patterns shows us that we are most likely to become what we see and are surrounded by.^{1,2} Likewise, we have an easier time believing we can achieve something when we see other people who look like us achieve similar goals. This is a challenge for African American/Black and Latinx youth who grow up in communities where access to higher education comes at a much higher cost, mentorship is scarce, and exposure is limited.

In just five years, Black Girl White Coat has grown into a 501(c)3 organization that has helped over 600 Black and Latinx students through our mentorship program, awarded over \$10,000 worth of scholarship to future health care professionals, and supplied numerous textbooks and other academic resources to those in need. Black and Latinx men and women are desperately needed to provide culturally competent quality care for a medical population that continues to grow in number and diversity. Support and representation have not previously been there; Black Girl White Coat exists to bridge that gap.

Black Girl White Coat is also exactly what I needed when I was younger. I hope everyone who encounters our organization soars to heights higher than I will ever reach. The potential has always been there; now we are tearing down barriers. However, we have more gaps to fill, especially when we look further down the line. More pipeline programs are needed in traditionally marginalized communities. Better support and retention strategies for faculty of color are needed in academic programs and throughout institutions. There is still so much work to be done ... Black Girl White Coat is just getting started.

Revolutionizing Information Access

JASKIRAT DHANOA, MD, PGY3; NICHOLAS STARK, MD, MBA, PGY4; CHRISTOPHER PEABODY, MD, MPH, University of California San Francisco, Department of

Emergency Medicine, Acute Care Innovation Center

Challenges presented by the COVID-19 pandemic pushed many emergency departments' stagnant information distribution systems to a breaking point, requiring rapid adaptation to support a constantly changing clinical care environment. San Francisco General Hospital (SFGH), a University of California San Francisco-affiliated site, was no exception. As our emergency department became overloaded with rapidly-changing clinical information, the Acute Care Innovation Center (ACIC) set out to improve access to critical clinical information. The ACIC uniquely brought together a group of residents, hospital leadership, and medical students to account for different perspectives and tackle problems in an innovative manner. Our team learned that clinicians felt overwhelmed by the volume and speed of changing clinical information that was communicated from emails to cloud folder uploads. Clinicians did not know where to find the most up-to-date information. And text-heavy documents were difficult to apply in real-time on shift.

The design process led our team to an idea that was profound in its simplicity: democratizing information through an open-access, mobile-friendly, centralized digital information hub. Today, that idea has become an evolving clinical information platform called E*Drive (<https://edrive.ucsf.edu>).


E*Drive currently hosts a broad array of clinical information, ranging from COVID-19 guidelines to announcements to discharge resources, and it displays this information in a simple, standardized flow-chart style to enable in-the-moment utilization on shift. The platform has been profoundly successful, increasing access to clinical information in our emergency department by over 230 percent (from 0.13 views/day with the legacy system to nearly 30 views/day in September 2021), with 77 percent of clinicians reporting improved access to clinical information and 70 percent endorsing improved efficiency on shift as a result of E*Drive.

Our team was able to build, launch, and sustain E*Drive for nearly free, all without in-depth tech experience. To do this, we built E*Drive on Drupal—our institution-supported web content management system—and utilized GoogleSlides to create the flow-chart style guidelines. E*Drive is easily accessible via a direct link in our medical record system or a short URL on any device with an internet connection. The platform layout is optimized for rapid information access with an average of three clicks from the homepage or via a robust search tool. The dynamic, modular nature of the E*Drive platform allows continued growth and evolution in response to user feedback. For example, we recently developed a first-of-its-kind Discharge Navigator tool (<https://edrive.ucsf.edu/dcnave>) that helps clinicians refer vulnerable patients to tailored community resources based on their demographics and needs. We also recently digitized frequently utilized forms, such as procedure consents, that previously needed to be accessed in cluttered filing cabinets.

E*Drive has revolutionized how our emergency department distributes and stores critical clinical information. By creating a system that is affordable, portable, and adaptable, our team



Dr. Dhanoa



Dr. Stark



Dr. Peabody

hopes to inspire other emergency physicians including residents to develop similar innovations to accelerate guideline accessibility in the future.

Histories of our Present Illness

LUKE MESSAC, MD, PHD, PGY4, Brown Emergency Medicine Residency

As a physician historian, I use techniques from history, anthropology, and epidemiology to study determinants of health outcomes. I completed my MD/PhD with a focus in the history of science, and have written about international opiate regulations, population control campaigns, economic indices, AIDS treatment activism, and hepatitis C diagnostic technologies. The aim of my research is to show how our way of delivering and paying for medical care developed, and how we might do better.



Dr. Messac

Today, I am studying the history of medical debt collection and the impact these debts are having on Americans' lives. Since the 1980s, unpaid medical debts have moved from obligations negotiated by doctors and patients to financial instruments traded on impersonal financial exchanges. Spurred in part by cuts in public funding and insurance companies' turn toward cost-sharing, hospitals have faced more bad debts. In response, health care institutions sent overdue bills to collection agencies and debt buyers. Divorced from the physicians' bond to patients, debt collectors exercise draconian techniques, using wage garnishments, liens on homes, and lawsuits to extract profits from patients. Aggressive debt collection and third-party debt purchasing have continued to spread.

Another area of my research examines how health professionals respond to scarcity. My book, *No More to Spend: Neglect and the Construction of Scarcity in Malawi's History of Medicine*, is a history of medical neglect in Malawi. Using the stories of doctors, patients, and political leaders, the book shows how colonial and postcolonial administrations used claims of scarcity to justify the dismal state of health care. Scarcity was not inevitable but was instead the product of choices by powerful actors to siphon financial resources away from medical care.

The COVID-19 pandemic highlighted the urgent need to study scarcity. New shortages have emerged, particularly in nursing staffing. This experience revealed the many tolls—psychological, economic, and clinical—exacted by not having enough resources to care for patients safely. In settings plagued by chronic scarcity, health care professionals face these inadequacies every day. Economists and psychologists have demonstrated how scarcity impairs the ability to make rational decisions. This has relevance to the practice of emergency medicine, particularly in low-income settings, where the constant pressure of not being able to practice the standard of care and the knowledge that one works in a system of tiered access can contribute to burnout, rushed diagnoses, and improper management. By understanding the pathophysiology of scarcity, we will improve outcomes and be better equipped to address health inequity. 📌

References

1. Childhood surroundings matter more than genes for would-be inventors. *The Economist*. 2017(12). <https://www.economist.com/united-states/2017/12/04/childhood-surroundings-matter-more-than-genes-for-would-be-inventors>.
2. Smith N. Nurture Counts as Much as Nature in Success. *Bloomberg Opinion*. 2017(12). <https://www.bloomberg.com/opinion/articles/2017-12-12/nurture-counts-as-much-as-nature-in-success>.

Toxicology Q&A Answer

QUESTION ON PAGE 17

Answer: Lily of the valley

Description

Although part of the asparagus family and potentially deadly, the flower has a scent that makes it one of the most beloved plants in the world. The flowers grow from underground rhizomes, so they will spread and take over an area of the garden if not planted with boundaries.

In the spring, each stem produces two long pointed leaves and a central raceme (a flower cluster with individual blossoms along a central stem) with five to 15 bonnet-shaped white flowers. Later in the growing season, the flowers are replaced by berries that range in color from red to orange.

Toxin and Dose

The plant contains a long list of toxins, mainly cardiac glycosides (some authors report 20–40)—primarily convallarin and convallamarin—that affect the heart and saponins that affect the gastrointestinal (GI) tract. The entire plant contains toxins; its leaves, berries, stems and roots are all poisonous.

It is reported that severe poisoning might occur after ingestion of a seemingly small amount or “two stems with leaves.” The water that cut stems are placed in may also contain enough toxins to poison someone trying to “taste the perfume.”

Symptoms of toxicity include nausea, vomiting, general malaise, chest pain, weakness, altered mental status, very slow heart rate, ir-

regular heartbeat, ectopy and cardiac arrest.

Treatment is primarily supportive. GI decontamination with activated charcoal can be considered. Although there is no clear antidotal therapy, the use of digoxin-specific Fab fragments has been suggested.

Similar Poisons

Other naturally occurring compounds with structures similar to these cardioactive steroids include bufadienolides (Bufo spp of toads), fireflies (Photinus spp), oleandrin (Nerium spp), cerebins (from *Cerbera odollam*, pong-pong or “suicide” tree) and ouabain (Acokanthera schimperi tree). This last one deserves some attention as it is where the African crested rat sources the poison it wicks into its fur—it’s the only known mammal that intentionally coats itself in poison! It’s totally worth a look if you are unfamiliar with this awesome animal.*

Cultural Background

Did you know the lily of the valley is the national flower of Finland?

It is often used in bouquets, in tabletop floral arrangements and as scent in soaps and perfumes. Bridal bouquets, including those of royal families, use it for its sweet perfume, and it was in the bouquets of Catherine, Duchess of Cambridge, and Princess Grace Kelly of Monaco. Plus, it is said to be Queen Elizabeth II’s favorite flower. In the language of flowers, lily



JASON HACK (OLEANDER PHOTOGRAPHY)

of the valley symbolizes purity, humility and a return to happiness.

The flower is traditionally associated with May Day, especially in France where the *mu-guet* is handed out at special events. The lily of the valley image is a frequently used motif in artwork, including those by Marc Chagall, Marx Reichlich, Carl Fabergé and others.



*Listen to this three-minute NPR podcast on the African crested rat. 🎧

LILY OF THE VALLEY

Convallaria majalis

COMMON NAMES: May lily, May bells, Our Lady’s tears —*convallis* (valley), *leiron* (lily) and *majalis* (May)



DR. HACK is chief of the division of medical toxicology and vice chair for research at East Carolina University in Greenville, North Carolina.

V I R T U A L

ACEP Advanced Pediatric Emergency Medicine Assembly

APRIL 11-13 • REGISTER TODAY!

Join us for this year’s Advanced Pediatric Emergency Medicine Assembly, a fully virtual conference, April 11-13, 2022

acep.org/pem

Be prepared for your next pediatric patient

ADVANCING EMERGENCY CARE

DEDICATED TO THE HEALTH OF ALL CHILDREN™

Approved for AMA PRA Category 1 Credit™
ADN_0322_MC1539_0222

Better prep. Better care.

Pass MyEMCert. Become a better physician.

PEERCert+ is designed specifically to help you succeed on MyEMCert™—and build knowledge to improve patient care.

- Questions tailored to each individual ABEM module
- New, updated, and thoroughly reviewed core content questions
- Board-style case series questions and Key Advances questions
- High-impact, colorful imagery enables better retention
- Create custom quizzes to strengthen weak areas

Sign up today at acep.org/peercertplus

Now Available

- Abdominopelvic
- Abnormal Vital Signs and Shock
- Head and Neck
- Neurology
- Nontraumatic Musculoskeletal
- Social and Behavioral Health
- Thoracorespiratory
- Trauma and Bleeding

Train. Test. Thrive.

ADVANCING EMERGENCY CARE

Approved for AMA PRA Category 1 Credits™

ADN_0322_MC1543_0222



The **T-STRIP** Wound Closure Mesh

DESIGNED FOR FINGERS



ALSO GREAT FOR OTHER SUPERFICIAL LACERATIONS & SKIN AVULSIONS



1. T-STRIP approximates wound edges & reduces wound tension.
2. Apply topical skin adhesive through T-STRIP to seal and protect the wound.
3. T-STRIP and TSA simply slough off in 8-14 days.

NO NEEDLES | NO SUTURES | NO FOLLOW UP

www.TheTstrip.com
info@theTring.com



Chair, Department of Emergency Medicine

The Aga Khan University (AKU) is a pioneering institution of higher education whose mission is to improve the quality of life in the developing world and beyond, through world-class teaching, research and healthcare delivery. AKU educates students for local and global leadership from campuses and teaching hospitals in six countries, primarily in Asia and Africa. It generates new knowledge to solve problems that affect millions of people, especially the most vulnerable. The University is a private, not-for-profit institution and part of the Aga Khan Development Network.

The Department of Emergency Medicine (ED) at AKU, Karachi, is the regional leader in establishing high quality clinical services and academic programmes. It has a robust research team and is actively involved in training and supervising residents, research fellows and facilitates faculty in capacity building in research through intramural and extra mural grants. The department also supports strong infrastructure for interdisciplinary research.

Responsibilities

- Support and mentor faculty as well as partner with internal and external stakeholders to meet the department's overall mandate
- Provide dynamic leadership to the department and fulfill the responsibility of its research, academic and service mandate
- Develop and implement a strategic vision for the department, fostering a strong research culture, and nurturing learning and training across programmatic levels
- Coordinate departmental activities with CETE
- Enhance departmental involvement in the academic activities of the Center, and forge new partnerships to increase the overall impact of the Department outside AKU

Requirements

- Must have MBBS/MD with postgraduate certification (FCPS, FRCS, Diplomate of American Board or equivalent qualification) preferably in Emergency Medicine
- Must have served at the academic rank of Associate Professor or Professor, with seasoned administration and leadership skills
- Must have high productivity and experience in research funding and publications, teaching, training and clinical service delivery
- Must be active in engaging teams and balancing multiple organizational tasks at a time

To Apply

Interested candidates are requested to submit a current resume along with summary of research and experience to human.resources@aku.edu

CALIFORNIA

ORANGE COUNTY/TUSTIN:

110 bed community hospital non-stemi/non-stroke. Only 0.8 pts/hr, competitive salary with incentives, 12 hr shifts.

LOS ANGELES:

Low volume 700/mo. Urgent care, non-paramedic receiving, less stress, 20 yr contract w/stable history. Patients 1/hr. Base + incentive.

NORWALK:

Low volume 600/mo. Paramedic receiving. Patients 1/hr. 10-year history stable. \$110/hr. 24 hr shifts available.

SAN FERNANDO VALLEY:

120 bed hospital med surg and psych, non-trauma non-stemi, paramedic receiving, 6 days 6 nights \$328,000 a year plus incentive. Now interviewing PAs&NPs for ER Panorama City location.

FAX CV to 323 306-0076 or call 747 283-1809 or email neubauerjanice@gmail.com




Be Part of a Great Experience!

21 Locations Across Texas
Flexible Hours
Robust Compensation Package
State of the Art Facility
Consistent Patient Flow
Fastest Growing ER in Texas
Satisfied Patients!
Join our team today!*

*Board Certified or Eligible in Emergency Medicine with at least 2 years of experience as an attending physician. Must have excellent patient satisfaction. Must have an active Texas Medical license.

SignatureCare
EMERGENCY CENTER

For more info, contact aevangelista@ercare24.com today!



HENRY J.N. TAUB
DEPARTMENT OF
EMERGENCY
MEDICINE

Academic & Clinical Faculty Opening


The Department of Emergency Medicine at Baylor College of Medicine (BCM) is looking for Faculty who are interested in a career in Academic Emergency Medicine. We are currently hiring faculty of all ranks commensurate with prior experience and seeking applicants who have demonstrated a strong interest and background in a variety of areas (eg. research, simulation, ultrasound, disaster medicine, ems, toxicology, etc...). Clinical opportunities are also available at our affiliated hospitals.

Baylor College of Medicine is located in the world's largest medical center in Houston, Texas. The Baylor Emergency Medicine Residency was established in 2010, and received department status in Jan 2017. Our residency program has grown to 16 residents per year in a 3-year format. We offer a highly competitive academic salary and benefits commiserate to academic level and experience.

Our academic program is based out of [Ben Taub General Hospital](#), [Baylor St. Luke's Medical Center](#), [DeBakey VA Medical Center](#) and [Texas Children's Hospital](#). Ben Taub General Hospital is the largest Level 1 trauma center in southeast Texas with certified stroke and STEMI programs that sees nearly 80,000 emergency visits per year. Baylor St. Luke's Medical Center is home to the Texas Heart Institute and is a tertiary referral center with multiple transplant programs and many high acuity patients. Texas Children's Hospital is consistently ranked as one of the nation's best, largest and most comprehensive specialty care pediatric hospitals. These affiliations, along with the medical school's preeminence in education and research, help to create one of the strongest emergency medicine experiences in the country.

MINIMUM REQUIREMENTS
Education: M.D. degree or equivalent
Experience: Previous experience in Research, Simulation and Toxicology strongly preferred but not required
Licensure: Must be currently boarded or board eligible in Emergency Medicine and eligible for licensure in state of Texas.

Those interested in a position or further information may contact [Dr. Dick Kuo](mailto:dckuo@bcm.edu) via email dckuo@bcm.edu or by phone at 713-873-2626. Please send a CV and cover letter with your past experience and interests.



HENRY J.N. TAUB
DEPARTMENT OF
EMERGENCY
MEDICINE

Academic & Clinical Faculty Opening

The Department of Emergency Medicine at Baylor College of Medicine (BCM) is looking for Faculty who are interested in a career in Academic Emergency Medicine. We are currently hiring faculty of all ranks commensurate with prior experience and seeking applicants who have demonstrated a strong interest and background in research simulation, ultrasound, or toxicology. Clinical opportunities are also available at our affiliated hospitals.

Baylor College of Medicine is located in the world's largest medical center in Houston, Texas. We offer a highly competitive academic salary and benefits commiserate to academic level and experience. Our academic program is based out of [Ben Taub General Hospital](#), [Baylor St. Luke's Medical Center](#) and [Texas Children's Hospital](#). Ben Taub General Hospital is the largest Level 1 trauma center in southeast Texas with certified stroke and STEMI programs that sees nearly 80,000 emergency visits per year. Baylor St. Luke's Medical Center is home to the Texas Heart Institute and is a tertiary referral center with multiple transplant programs and many high acuity patients. Texas Children's Hospital is consistently ranked as one of the nation's best, largest and most comprehensive specialty care pediatric hospitals. These affiliations, along with the medical school's preeminence in education and research, help to create one of the strongest emergency medicine experiences in the country.

MINIMUM REQUIREMENTS
Education: M.D. degree or equivalent
Experience: Previous experience in Research, Simulation and Toxicology strongly preferred but not required
Licensure: Must be currently boarded or board eligible in Emergency Medicine and eligible for licensure in state of Texas. Those interested in a position or further information may contact [Dr. Dick Kuo](mailto:dckuo@bcm.edu) via email dckuo@bcm.edu or by phone at 713-873-2626. Please send a CV and cover letter with your past experience and interests.

Baylor College of Medicine (www.bcm.edu) is recognized as one of the nation's premier academic health science centers and is known for excellence in education, research, healthcare and community service. Located in the heart of the world's largest medical center (Texas Medical Center), Baylor is affiliated with multiple educational, healthcare and research affiliates (Baylor Affiliates).

The Henry JN Taub Department of Emergency Medicine at Baylor College of Medicine seeks a Vice Chair of Research to oversee research operations for the department.

Salary, rank, and tenure status are contingent upon candidate qualifications. The rank and tenure status awarded will be based upon qualifications in alignment with Baylor College of Medicine's promotion and tenure policy.

Qualified applicants are expected to have a research record with significant extramural funding and leadership skills to develop a strong multidisciplinary collaborative Emergency Medicine research program and continue to grow current departmental research efforts. In addition to the above responsibilities, other duties may be assigned by the Chair.

Please include a cover letter and current curriculum vitae to your application.

This position is open until filled. For more information about the position, please contact Dick Kuo, MD via email [dckuo@bcm.edu].

MINIMUM REQUIREMENTS
Education: M.D. degree or equivalent
Experience: Research Fellowship not required for application
Licensure: Must be currently boarded in Emergency Medicine and eligible for licensure in state of Texas.


ACEP Now CLASSIFIED ADVERTISING
The Official Voice of Emergency Medicine

ACEP Now has the largest circulation among emergency medicine specialty print publications with nearly 40,000 BPA-Audited subscribers including about 29,000 ACEP members.

Your ad will also reach the entire 1,800 members of the Society of Emergency Medicine Physician Assistants (SEMPA).

To place an ad in ACEP Now's Classified Advertising section please contact:

Kelly Miller
kmiller@mrvica.com
(856) 768-9360



Visit Us at
scp-health.com/heal



Discover What Together Can Do

Join Our Clinical Team

- ✔ Competitive Sign-On Packages
- ✔ Physician-Led Company
- ✔ Clinician Support
- ✔ Leading Benefits

Our dedicated recruiters are focused on one thing: finding you the right career fit. Scan the QR code to find your next position with SCP Health.





Penn State Health Emergency Medicine

About Us:

Penn State Health is a multi-hospital health system serving patients and communities across 29 counties in central Pennsylvania. The system includes Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital, and Penn State Cancer Institute based in Hershey, PA; Penn State Health Holy Spirit Medical Center in Camp Hill, PA; Penn State Health St. Joseph Medical Center in Reading, PA; and more than 2,300 physicians and direct care providers at more than 125 medical office locations. Additionally, the system jointly operates various health care providers, including Penn State Health Rehabilitation Hospital, Hershey Outpatient Surgery Center, Hershey Endoscopy Center, Horizon Home Healthcare and Pennsylvania Psychiatric Institute.

In December 2017, Penn State Health partnered with Highmark Health to facilitate creation of a value-based, community care network in the region. Penn State Health shares an integrated strategic plan and operations with Penn State College of Medicine, the university’s medical school.



We foster a collaborative environment rich with diversity, share a passion for patient care, and have a space for those who share our spark of innovative research interests. Our health system is expanding and we have opportunities in both an academic hospital as well community hospital settings.

Benefit highlights include:

- Competitive salary with sign-on bonus
- Comprehensive benefits and retirement package
- Relocation assistance & CME allowance
- Attractive neighborhoods in scenic Central Pennsylvania



PennState Health

FOR MORE INFORMATION PLEASE CONTACT:

Heather Peffley, PHR CPRP - Penn State Health Physician Recruiter
hpeffley@pennstatehealth.psu.edu

Penn State Health is fundamentally committed to the diversity of our faculty and staff. We believe diversity is unapologetically expressing itself through every person’s perspectives and lived experiences. We are an equal opportunity and affirmative action employer. All qualified applicants will receive consideration for employment without regard to age, color, disability, gender identity or expression, marital status, national or ethnic origin, political affiliation, race, religion, sex (including pregnancy), sexual orientation, veteran status, and family medical or genetic information.



US Acute Care
Solutions



Alteon
HEALTH

YOU CAN **SAY OWNERSHIP MATTERS.**
OR YOU CAN **MAKE IT MATTER.**

US Acute Care Solutions bought back our group from private equity in 2021. Now in 2022, we have bought out Alteon's private equity partners too, granting more than 450 Alteon physicians ownership in their group. In doing so, we have further strengthened our patient-centered practice, which is owned and led by physicians. At USACS, we believe what you believe: Our patients matter, our colleagues matter, our specialties matter and our careers matter. **At USACS, ownership matters.**

To our new colleagues from Alteon we say: **Welcome aboard!** We're proud to unite with you to care for our shared patients and to preserve the future of our specialties. **Together, we own the future!**

OWN YOUR FUTURE JOIN USACS
Learn more at [USACS.com](https://www.usacs.com)



US Acute Care
Solutions